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Abstract
Prostate cancer is the most commonly diagnosed form of cancer in men in Canada and 
the United States. Both genetic and environmental factors contribute to development and 
progression of many cancers, including prostate cancer, with prostate cancer affecting 
many men worldwide. As such there have been many studies into the effects of natural 
products on this form of cancer. This work demonstrates the effects of magnolol, a 
compound found in the roots and bark of the magnolia tree Magnolia officinalis, on the 
behavior of LNCaP, DU145 and PC3 human prostate cancer cells in vitro. Magnolol was 
found to be cytotoxic to human prostate cancer cells, and to affect cell cycle progression 
of DU145 and PC3 cells, resulting in alterations to the cell cycle and subsequently 
decreasing the proportion of cells entering the G2/M-phase of the cell cycle. Magnolol 
inhibited the expression of cell cycle regulatory proteins including cyclins A, B1, D1 and 
E, as well as CDK2 and CDK4. Protein expression levels of pRBp107 decreased, while 
pRBp130 and p27 protein expression levels increased in response to magnolol exposure. 
PC3 cells exposed to magnolol exhibited decreased protein expression of ornithine 
decarboxylase, a key regulator in polyamine biosynthesis, as well as affecting expression 
of other proteins involved in polyamine biosynthesis and catabolism. Furthermore, 
protein expression of the R2 subunit of ribonucleotide reductase was significantly 
decreased. Cellular signaling pathways were also assayed to determine which, if any, of 
these pathways magnolol exposure would alter. Finally, magnolol was found to affect the 
expression of IGF-I and associated proteins in LNCaP and PC3 cells. In both cell lines, 
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protein expression of IGF-I and IGFBP-5 were significantly decreased while protein 
expression of IGFBP-3 was significantly increased. The results obtained throughout this 
thesis suggest that magnolol can affect the behavior of human prostate cancer cells in 
vitro, suggesting that magnolol may have potential as a novel anti-prostate cancer agent.
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CHAPTER ONE
Introduction and Literature Review
1.1 Introduction
Prostate cancer is the most common form of cancer among men in Canada and the United 
States, and the second most common form of cancer among men worldwide (ASC 2011; 
CCS 2013). The complex nature of the disease combined with the difficulties in finding 
effective treatments with few side effects have led to a consistent search for new 
compounds with chemopreventative and chemoprotective properties. One area of interest 
is the search for novel, naturally occurring, anti-cancer compounds. Many herbal and 
phytochemical compounds have been shown to have some chemopreventative effect, and 
there is evidence to suggest that a relationship between these compounds in the diet and 
incidence of cancer exists (Aggarwal and Shishodia 2006; Bemis et al. 2006; Neto 2011; 
Stein and Colditz 2004; Tan et al. 2011). One such natural product is magnolol, a 
compound found in the roots and bark of the magnolia tree Magnolia officinalis. 
Magnolol has previously been shown to induce apoptosis and to decrease metastasis in 
human prostate cancer cells in vitro, as well as having a variety of other anti-cancer 
effects on various other types of cancer in vitro (Hwang et al. 2013; Lee et al. 2009). The 
work presented seeks to further demonstrate the anti-cancer effects of magnolol in human 
prostate cancer cells in vitro by investigating the effect of magnolol on cellular growth 
and proliferation lined activities within the cell.
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1.1.1 Research Rationale, General Hypothesis and Objectives
Previous research on the effects of magnolol on various human cancer cell lines has been 
conducted. Magnolol is known to inhibit metastasis in human ovarian cancer cells in 
vitro, and to induce apoptosis in human gastric cancer cells in vitro (Chuang et al. 2011; 
Rasul et al. 2012). Furthermore, magnolol has been reported to suppress proliferation and 
activate apoptosis in human colon and liver cancer cells in vitro and in vivo, as well as 
cause cell cycle arrest in human colon cancer cells in vitro (Hsu et al. 2007; Lin et al. 
2001; Lin et al. 2002). Finally, magnolol has been shown to inhibit cellular proliferation 
and induce apoptosis in glioblastoma cells in vitro and to cause cell cycle arrest in human 
urinary bladder cancer cells in vitro (Chen et al. 2009; Chen and Lee 2013; Lee et al. 
2008a).
 Specific to prostate cancer, magnolol has previously been shown to induce 
apoptosis and to suppress metastasis in human prostate cancer cells in vitro (Hwang and 
Park 2010; Lee et al. 2009). The precise effects of magnolol on cellular growth and 
proliferation in human prostate cancer cells have not, however, been examined. The 
purpose of this work is to expand the current understanding of magnolol as a potential 
anti-prostate cancer compound by focusing on the magnolol-mediated cellular response 
with specific regard to cellular growth and proliferation. It was therefore hypothesized 
that magnolol will inhibit cancer cell growth in vitro, specifically that magnolol will 
affect human prostate cancer cells in vitro by affecting activities linked to cellular growth 
and proliferation.
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 The specific objectives of this thesis are:
1) Determination of the effect of magnolol on cell cycle events.
2) Determination of the effect of magnolol on cellular proliferation-
linked activities.
3) Determination of the effect of magnolol on insulin-like growth factor-I 
and associated proteins.
 Each of the three objectives outlined above was achieved, and have been 
individually submitted for publication as research manuscripts. All three of those 
manuscripts have been published in academic journals. As such, these objectives have 
been organized as three separate manuscripts which comprise Chapters Two, Three and 
Four of this thesis. Together, these chapters represent the knowledge/discovery section of 
this publication-style thesis.
3
1.2 Literature Review
1.2.1 Cancer
Cancer has been known to medicine since ancient times. The earliest evidence of cancer 
can be found in Egyptian manuscripts dating back to 1600 BCE (Sudhakar 2009). In 
these manuscripts it was noted that the appropriate treatment for surface tumors was 
surgical removal or cauterization, while deep tissue tumors were considered untreatable 
(Sudhakar 2009). The word cancer first appears as the Greek karkinos described by 
Hippocrates (460-370 BCE) (Sudhakar 2009). Hippocrates is considered the first Greek 
physician to have studied the specifics of cancer but, as with the ancient Egyptians, 
considered deep or “hidden” cancers to be incurable as the patients often lived longer if 
left untreated (Karpozilos and Pavlidis 2004). Later Greek physicians, such as Galen 
(129-199), determined that there was a connection between diet, environment and cancer 
occurrence (Karpozilos and Pavilidis 2004). Despite these discoveries, the treatment of 
cancer remained essentially unchanged from the methods of the ancient Egyptians 
throughout the middle ages. 
 Today, cancer is considered the fastest growing disease worldwide with regard to 
new diagnoses and deaths and is becoming the leading cause of death in developed 
countries like Canada, where cancer is the leading cause of death, and the United States 
of America where it is the second leading cause of death (ACS 2011, 2014; CCS 2013). 
In developing countries cancer is second only to heart disease as the leading cause of 
death (Popat et al. 2013). Lung cancer is the leading cause of new cancer cases in men 
while breast cancer is the leading cause in women worldwide (ACS 2011). In developed 
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countries prostate cancer is the leading cause in men while breast cancer remains the 
leading cause in women (ASC 2011). In 2008, 12.7 million new cases of cancer were 
estimated to have occurred worldwide and by 2030 it is estimated that there will be 21.4 
million new cases of cancer per year (ACS 2011). In 2013, an estimated 187600 
Canadians developed cancer and 75500 Canadians are estimated to have died of cancer 
(CCS 2013). It is estimated that 2 in 5 Canadians will develop cancer in their lifetime and 
that 1 in 4 Canadians will die of cancer (CCS 2013). Lung, colorectal, breast and prostate 
cancer each account for 10% or more of all cancer death in each sex in Canada and more 
than half of all new cases will be one of these types of cancer (CCS 2013).
 Increasing cancer rates have been linked to an aging population, with 78% of all 
new diagnoses occurring after age 55 worldwide, and 88% of all diagnoses in Canada 
occurring after age 50 (ACS 2011; CCS 2013). Within Canada there are higher rates of 
cancer on the east coast, with rates gradually decreasing westward (CCS 2013). Other 
factors contributing to increased risk of cancer are: tobacco use, physical activity, weight, 
diet, alcohol use and sun exposure (Stein and Colditz 2004). Of particular concern is the 
association between obesity and cancer, with roughly 25% of Canadian adults considered 
obese according to measurements taken from 2007-2009 and increasing rates of obesity 
in both adults and children in both developed and developing countries (PHAC 2011; 
WHO 2000). As rates of cancer and obesity both increase the relation between the two is 
of increasing importance as diet and body weight are the two most common causes of 
cancer in the United States (Wolin et al. 2010). Obesity has been linked to increased 
activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-
5
kinase (PI3K) cellular signaling pathways as well as increased expression of insulin-like 
growth factor-I (IGF-I) (Vucenik and Stains 2012). These processes are all associated 
with cellular proliferation and increases in expression of proteins involved in these 
pathways would lead to an increased propensity for cancer cell development.
 Cancer is typically recognized as a group of diseases representing the 
uncontrolled growth and spread of cells (ACS 2014). While normal cellular proliferation 
follows a strictly controlled sequence of growth, division and death, cancer cells undergo 
growth and proliferative processes in an unregulated manner and avoid apoptosis. 
Hanahan and Weinberg (2000, 2011) have listed six hallmark characteristics of cancer 
cells. Those characteristics which all forms of cancer share are: sustaining proliferative 
signaling, evading growth suppressors, activating invasion and metastasis, enabling 
replicative immortality, inducing angiogenesis, and resisting cell death. This list was also 
updated to include two additional emerging hallmarks: deregulating cellular energetics 
and avoiding immune destruction; and two enabling characteristics: genome instability/
mutation and tumor-promoting inflammation (Hanahan and Weinberg 2011). These 
hallmarks and enabling characteristics represent the key processes involved in cancer 
treatment and cancer research as compounds which disrupt these hallmarks would 
represent a potentially novel compound for cancer treatment. As all of these hallmarks 
appear necessary for cancer development, cancer is a complex and widely diverse disease 
with each of these characteristics developing independently and in different ways. As this 
thesis is primarily concerned with cellular proliferation it is important to note that 
Hanahan and Weinberg (2011) recognized the hallmark of sustaining proliferative 
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signaling as “arguably the most fundamental trait” in cancer development. Those 
pathways proposed as most commonly activated in carcinogenesis are the MAPK and 
PI3K/Akt signaling pathways (Hanahan and Weinberg 2011). In their discussion of the 
“evading growth suppressors” hallmark Hanahan and Weinberg (2011) found the RB 
growth suppressor proteins as the most typically downregulated. This also means that as 
cells develop those traits needed for cancer development there is a selection whereby 
cells which are growing faster, dividing more often and resisting cell death longer will be 
selected for. This allows for further characteristics of cancerous cells to develop simply 
because these cells are behaving in ways that non-cancerous cells do not. This kind of 
selection of has been linked to genetic instability as cells exhibiting an increased 
propensity for genetic instability, and thereby gaining the hallmarks of cancer through 
DNA damage, acquire cancerous traits and retain their instability which allows for the 
possibility of acquiring further traits (Cahill et al. 1999).
 Treatment of cancer today includes such methods as surgical intervention, 
radiation therapy, chemotherapy, hormone therapy and monitoring (DeSantis et al. 2014). 
One challenge in developing new treatments for cancer is in targeting those treatments to 
specific tumor types, this kind of targeting leads to maximized efficacy with minimal 
toxicity to non-cancerous cells (Golub et al. 1999).
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1.2.1.1 Prostate Cancer
The prostate gland is an accessory organ involved in male reproduction. The prostate 
gland is composed of both epithelial and stromal cells and it is the epithelial cells which 
typically prove cancerous as these cells lose the need for support by the stromal cells 
(Russell et al. 1998). Prostate cancer is the second most common cancer in men 
worldwide and the most common cancer in men in Canada (ACS 2011; CCS 2013). It is 
estimated that 24.5% of all new cancer diagnoses in men in 2013 were prostate cancer 
and that Canadian men have a 1 in 7 chance of developing prostate cancer in their 
lifetime (CCS 2013). As with other forms of cancer, the probability of prostate cancer 
diagnosis increases with age. Prostate cancer is rarely diagnosed in men under 50 years, 
with the majority of diagnoses occurring between the ages of 55 and 64 years worldwide 
(Baade et al. 2009; Dunn and Kazer 2011). Traditionally, those diagnosed with prostate 
cancer at a younger age present with more aggressive disease and poorer overall 
prognosis but as testing methods develop and improve there has been a decrease in age at 
diagnosis and that disease is less severe at diagnosis due to early detection (Baade et al. 
2009). 
 Risk factors for prostate cancer include: family history, advanced age, race, diet 
and previous vasectomy (Dunn and Kazer 2011; Pienta and Esper 1993). It is of 
particular interest that prostate cancer has been associated with a Western lifestyle, with 
lower rates of prostate cancer occurring in Asian countries (Grönberg 2003; Hsing and 
Chokkalingam 2006). The connection between the increased rate of prostate cancer in 
Western countries appears to be largely due to diet, with increased red meat consumption, 
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increased availability of androgens and estrogens, and increased dietary fat intake 
(Grönberg 2003; Hsing and Chokkalingam 2006). This is further supported by the lower 
incidence of prostate cancer in populations with an Asian or vegetarian diet (Grönberg 
2003; Hsing and Chokkalingam 2006). It has also been suggested by Pienta and Esper 
(1993) that socioeconomic status and occupation may also play a role in prostate cancer 
risk, but these factors have not been conclusively linked to the disease. 
 After diagnosis there are several treatment options available for prostate cancer, 
the most common of which include: active surveillance, prostatectomy, external radiation 
therapy, brachytherapy, cryotherapy, hormone therapy and chemotherapy (Dunn and 
Kazer 2011). Active surveillance is most commonly used after initial diagnosis for early 
stage prostate cancers or in individuals who would otherwise have a life expectancy of 
under 10 years (Dunn and Kazer 2011). This allows for monitoring of disease 
advancement while maintaining the highest quality of life for as long as possible as other 
treatment options are more extreme in nature. Chemotherapy is generally used as the last 
option for advanced, metastatic disease (Dunn and Kazer 2011).
 As noted above, treatment of prostate cancer is usually based upon disease 
progression. Androgens are important for the growth, development and proliferation of 
normal prostate cells as well as for early stages of prostate cancer. Prostate cancer tumor 
growth is initially androgen dependent, with cancer cells requiring the presence of 
androgens to divide as would normal prostate cells (Feldman and Feldman 2001; 
Galbraith and Duchesne 1997). At this stage androgen ablation, through either surgical or 
chemical deprivation of androgens, is effective at slowing or causing regression of 
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prostate cancer tumor growth (Feldman and Feldman 2001). In normal prostate cells and 
in androgen dependent prostate cancers the loss of androgens will result in slowed 
cellular proliferation and increased apoptosis (Galbraith and Duchesne 1997). Generally 
the regression of tumor growth resulting from androgen ablation is a temporary solution, 
with the development of androgen independent prostate cancer occurring eventually. 
Prostate cancer typically progresses by changing from androgen dependence, where 
androgens are required for cellular growth and division, to androgen sensitivity, where 
cells will grow and divide faster in the presence of androgens but those androgens are not 
required for cellular growth, to full androgen independence (Russell et al. 1998). This 
kind of progression will happen almost invariably after androgen ablation therapy, 
typically taking about 24 months for androgen independence to fully develop after 
treatment (Russell et al. 1998). It has been posited that all metastatic prostate cancers will 
eventually become androgen independent (Galbraith and Duchesne 1997). This 
development occurs because androgen dependent prostate cancer cells are being selected 
against due to the loss or limitation of androgens, allowing androgen independent cells to 
gain a selective growth advantage. Androgen independence can be acquired though 
several different kinds of genetic mutation which may allow androgen receptors to 
stimulate growth in the absence of androgen, allow receptors to become more sensitve to 
low levels of androgens or to become sensitive to non-androgen steroids hormones 
(Feldman and Feldman 2001; Galbraith and Duchesne 1997). These androgen 
independent cells represent a much more aggressive form of prostate cancer and it is at 
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this stage that chemotherapy is normally used in disease treatment (Dunn and Kazer 
2011).
 As the aggressiveness of disease increases so too does the rate of metastasis, with 
bone being the most common site of metastatic invasion (Dunn and Kazer 2011). It was 
found that 84% of metastatic prostate cancers in a US population between 1998 and 2010 
showed metastasis to bone, with the next most common site being lymph nodes at 10.6% 
(Gandaglia et al. 2014). The basis of this preference for bone metastasis is not well 
understood but several theories are being investigated. The most popular hypotheses 
concern bone presenting a microenvironment closely matching the needs of prostate 
cancer cells (Gandaglia et al. 2014; Rucci and Angelucci 2014). Rucci and Angelucci 
(2014) further suggest that growth factors stored in the bone matrix become available to 
prostate cancer cells and so stimulate proliferation. This hypothesis is further expanded 
by Autio and Morris (2013) who suggest that the ionized calcium released by osteoclast 
activity stimulates proliferation as well as encouraging cells to migrate to bone. Finally, 
the veins between the prostate and lower vertebrae may provide direct access for prostate 
cancer to invade the spinal cord (Gandaglia et al. 2014; Rucci and Angelucci 2014).
11
1.2.1.2 In Vivo Models of Prostate Cancer
For research on prostate cancer to progress, a model of the disease is necessary for 
researchers to work with. Ideally, this model would closely mimic clinical conditions of 
human prostate cancer such as occurring spontaneously, having a reasonably slow 
doubling time, be androgen dependent or sensitive with the ability to progress to 
androgen independence, produce prostate specific antigen and commonly metastasize to 
bone and lymph nodes (Bosland et al. 1996; Russell et al. 1998). Several different animal 
models are in use for prostate cancer research, including rat and dog models which are 
capable of spontaneously developing carcinoma of the prostate, but the tumors developed 
do not behave as human prostate cancers do and are only useful as models of certain 
stages of tumor growth and cancer development (Lamb and Zhang 2005).
 Genetically engineered mouse models of prostate cancer are also in use, with one 
of the earliest developed being the transgenic adenocarcinoma of the mouse prostate 
(TRAMP) model (Lamb and Zhang 2005). TRAMP mice were developed in the early 
1990’s as a spontaneously occurring model of prostate cancer (Greenberg et al. 1995; 
Valkenburg and Williams 2011). To produce TRAMP mice, a viral oncogene was inserted 
which is specifically activated in the mouse prostate and leads to the downregulation of 
p53 and pRB expression (Greenberg et al. 1995; Valkenburg and Williams 2011). 
TRAMP mice have a high rate of tumor incidence and the disease presented mimics the 
histology and pathology of human disease, making them a popular model in nutrition and 
chemoprevention studies (Lamb and Zhang 2005). The strength of the TRAMP model is 
that it represents a spontaneous cancer of the mouse prostate which mimics the 
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progression of human disease in that it can progress to androgen independence and is 
metastatic (Valkenburg and Williams 2011). This allows for the in vivo study of a cancer 
in the animal in which it has originally occurred. The weakness of the TRAMP model is 
that cancers are not of the same epithelial origin as in human disease and metastasis to 
bone rarely occurs (Valkenburg and Williams 2011). 
 Finally, immunodeficient mice such as the nude mouse model have been used, 
where human prostate cancer cells are implanted into these mice (Lamb and Zhang 
2005). Nude mice are deficient in T lymphocytes due to the lack of a thymus gland and 
therefore show no immune response to foreign tissue (Valkenburg and Williams 2011). 
This allows for human prostate cancer cells to be xenografted into these mice where they 
can develop into tumors without being destroyed by the mouse immune response. The 
advantage to using such a xenograft model lies in the ability to study human prostate 
cancer cells in vivo, undergoing angiogenesis, metastasis and hormonal regulation in the 
context of a whole animal. Using this xenograft model does, however, require the 
development of human prostate cancer tissue culture cell lines. The disadvantages to 
using the nude mouse xenograft model is that the compromised immune system of these 
animals may affect tumor progression and metastasis, causing changes which many not 
occur in animals with functioning immune response to tumors, and that this model does 
not adequately represent the interaction of cancerous cells within the microenvironment 
(Valkenburg and Williams 2011).
  The mouse models have various strengths and weaknesses in the context of 
prostate cancer research. The support for mouse models arises from the ability to study 
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cancer cells in vivo, the fact that the mouse and human genomes share 95% similarity, 
mice are easily genetically modified, develop quickly and are easy to raise in the large 
numbers required for study (Valkenburg and Williams 2011). Some problems with the 
mouse model of prostate cancer do, however, remain. Naturally occurring prostate cancer 
is uncommon in mice, and the mouse and human prostates are dissimilar in structure 
(Valkenburg and Williams 2011). Most mouse metastases tend to originate from 
mesenchymal cells, whereas most human metastases originate from epithelial cells 
meaning that the mouse models represent a different form of disease (Valkenburg and 
Williams 2011). Lastly, bone metastasis is very uncommon in mice, even when implanted 
with human prostate cancer cells, while bone is the most common site of metastasis in 
humans (Valkenburg and Williams 2011). As no idealized animal model exists, with 
spontaneous prostate cancer development being rare in animals other than humans, 
several human prostate cancer tissue culture cell lines have been developed for the study 
of prostate cancer (Sobal and Sadar 2005).
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1.2.1.3 In Vitro Models of Prostate Cancer
Due in part to the limitations of producing animal models of prostate cancer (ethical 
concerns, expense and lack of appropriate model), several human prostate tissue culture 
cell lines have been developed (Sobal and Sadar 2005). The first such attempts at 
isolating a human prostate cancer tissue culture were made as early as 1917 but these 
initial efforts provided only short-term, primary cultures (Burrows et al. 1917; van 
Bokhoven et al. 2003). Progress toward a viable long term tissue culture of human 
prostate cancer was not made until the 1970’s, yet these cell lines were susceptible to 
contamination from other cells in culture and many were found to have been 
contaminated by other tissue cultures such as HeLa cells (van Bokhoven et al. 2003). 
Prostate cancer has proven to be one of the most difficult cell types from which to 
establish a continuous cell line because of the various different tissue types found in the 
prostate (Russell et al. 1998; van Bokhoven et al. 2003). As such, development of these 
cell lines often involves metastatic cancers as tumors found in these metastasis represent 
a homogeneous population comprised only of malignant cancer cells. By developing 
tissue cultures from specimens taken from these sites of metastasis the issue of having 
cells representative of both normal prostate and cancerous prostate is avoided (Stone et 
al. 1978). The three “classical” human prostate cancer tissue culture cell lines were 
developed in exactly this way. 
 There are three “classical” in vitro models of human prostate cancer: LNCaP, 
DU145 and PC3 cells. These three cell lines remain the most popular models for the 
majority of prostate cancer research (Sobal and Sadar 2005). As it is necessary for models 
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to closely represent clinical conditions of human prostate cancer these three cell lines are 
useful as they present a natural progression of disease when used together (Bosland et al. 
1996; Nair et al. 2004). LNCaP cells represent a poorly malignant and androgen-sensitive 
prostate cancer, DU145 cells are moderately malignant and androgen-independent and 
PC3 cells are a highly malignant prostate cancer cell line which is also androgen-
independent (Nair et al. 2004). These cell lines are recognized as being useful to the 
study of prostate cancer and have previously been used to justify clinical trials (Lippman 
et al. 2009). A study by van Bokhoven et al. (2003) showed that the karyotypes of these 
“classical” cell lines remained similar to those originally reported and determined that 
these in vitro models of prostate cancer retained a high level of stability over time. It is 
important, however, to keep in mind the number of times a tissue culture cell line has 
been subcultured to ensure that experimental results are as accurate and repeatable as 
possible. Passage number refers to the number of times a tissue culture cell line has been 
transferred from one vessel to another, or subcultured, for the purpose of propagating 
cells and maintaining tissue culture health (ATCC 2010). Researchers are becoming 
increasingly aware that the characteristics of cell lines can alter as high passage numbers 
are reached (ATCC 2010). High passage numbers can lead to changes in morphology, 
response to experimental compounds and growth rates so it is important to avoid using 
cells which have been subcultured too many times (ATCC 2010). This can be achieved by 
cryopreserving cells at low passage numbers and frequently replacing tissue cultures with 
these preserved low passage cells as the passage number of cultures increases. PC3 cells, 
representing the most advanced disease state of the three models, have been chosen as the 
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primary tissue culture to be studied in this thesis with supporting data from DU145 and 
LNCaP cells included in selected studies. The decision to focus on PC3 cells, with select 
supporting data from other cell lines, is consistent with previous in vitro studies on 
human prostate cancer cells (Lee et al. 2009).
 LNCaP cells were isolated from a lymph node metastasis of prostate cancer in a 
50 year old, white male (Horoszewicz et al. 1980). Unlike previously established cell 
lines, LNCaP cells were found to be weakly adherent and much slower growing with a 
doubling time of approximately 72 h (Horoszewicz et al. 1980). This cell line also 
retained its malignant properties when implanted into nude mice after cell culture but 
would establish much faster in male mice than in females (Horoszewicz et al. 1980, 
1983). LNCaP cells were found to be capable of growth in the absence of androgens but 
to grow much faster when androgens were present, establishing that LNCaP cells were 
androgen-sensitive (Horoszewicz et al. 1980, 1983).
 DU145 cells were isolated from a brain metastasis of prostate cancer in a 69 year 
old, white male (Stone et al. 1978). These cells were described as being a poorly 
differentiated adenocarcinoma which changed little in 2 years of subsequent tissue culture 
showing a doubling time of approximately 34 h (Stone et al. 1978). The cells were noted 
as androgen-independent as cells would grow equally well in either the presence or 
absence of androgens (Stone et al. 1978).
 PC3 cells were isolated from a lumbar vertebrae metastasis of prostate cancer in a 
62 year old, white male (Kaighn et al. 1979). These cells were described as having good 
adhesion to tissue culture dishes and showing reliable growth with a doubling time of 
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approximately 33 h (Kaighn et al. 1979). It was noted that no growth factors stimulated 
the growth of PC3 cells, that cells required minimal serum and that the addition of 
dihydrotestosterone did not affect cellular growth; this androgen-independence was 
confirmed in that tumors readily developed when implanted in either male or female nude 
mice (Kaighn et al. 1979). This line has subsequently been recognized as the most 
aggressive of the “classical” prostate cancer tissue cultures (Sobal and Sadar 2005).
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1.2.2 The Magnolia Tree, Magnolia officinalis and Magnolol
The magnolia tree Magnolia officinalis is widely used in traditional Chinese medicine 
(Figure 1.1 A). These trees are found throughout subtropical China at 300-2000 m 
elevation, typically in broad leaf forests (He et al. 2009). Magnolia officinalis trees 
typically have a life span of over 100 years and do not bear fruit until approximately 15 
years of age (He et al. 2009). The roots and bark of Magnolia officinalis, known as the 
herb Hou pu, have traditionally been used to treat a variety of symptoms and complaints 
such as gastrointestinal disorders, anxiety and allergies (Lee et al. 2011). More recently, 
extracts from magnolia bark have shown anti-cancer, anti-inflammatory, anti-oxidant, 
anti-depressant, anti-Alzheimer's and anti-atherosclerosis effects (Lee et al. 2011).
 This bark was found to contain several biologically active compounds including 
honokiol, 4-O-methylhonokiol, obovatol and magnolol with magnolol being the most 
abundant (Lee et al. 2011). Magnolol is a phenolic compound with the chemical structure 
5,5’-diallyl-2,2’-dihydroxylbiphenyl (Figure 1.1 B) (Bang et al. 2000). Compounds like 
magnolol are gaining increased attention due to their therapeutic potential and historical 
usage (Chen et al. 2011; Mainardi et al. 2009). As increasing research on magnolol is 
being undertaken it has been found that magnolol can exhibit anti-microbial activity at a 
concentration of 25 µg/ml and anti-fungal activity at a concentration of 25-100 µg/ml 
(Bang et al. 2000; Ho et al. 2001). Magnolol has also been found to display a variety of 
medicinal effects originally attributed to magnolia bark, as well as being widely 
bioavailable (Chen et al. 2011). These attributes make magnolol an important candidate 
for research into bioactive natural compounds.
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Figure 1.1: Magnolia officinalis and Magnolol. (A) The leaf, flower and bark of the 
magnolia tree Magnolia officinalis (Adapted from Chen et al. 2011). (B) The chemical 
structure of magnolol, 5,5’-diallyl-2,2’-dihydroxylbiphenyl (C18H18O2).
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1.2.2.1 Effects of Magnolol on Cancer
Of particular interest are the anti-cancer and anti-prostate cancer effects attributed to 
magnolol exposure. A variety of studies have been done on magnolol and cancer and they 
show that this compound is capable of inducing apoptosis and preventing both metastasis 
and cellular growth and proliferation. Magnolol has previously been shown to induce 
apoptosis in a variety of human cancer cell lines, both in vitro and in cancerous cells 
implanted into animal models. Apoptosis was induced in HepG2 human hepatoma and 
COLO205 human colon cancer cell lines, both in vitro and in vivo (Lin et al. 2001, 2002). 
Apoptosis induction also occurred in human gastric cancer cells, glioblastoma cells and 
breast cancer cells exposed to magnolol (Chen and Lee 2013; Rasul et al. 2012; Zhou et 
al. 2013). With regard to metastasis, magnolol has been shown to reduce metastatic 
potential in human ovarian cancer cells (Chuang et al. 2011).
 Magnolol has also previously been shown to affect cellular growth and 
proliferation in many different human cancer cell lines in vitro. This anti-proliferative 
effect is generally measured though cell cycle arrest and accompanied by increased 
expression of either p21 or p27, two cyclin dependent kinase inhibitors. Cell cycle arrest 
occurred at different stages of the cell cycle across different cell lines. Human gastric 
cancer cells were arrested in the S phase of the cell cycle (Rasul et al. 2012). Human 
breast cancer cells and human urinary bladder cancer cells were both arrested in the G2/
M phase of the cell cycle (Lee et al. 2008a; Zhou et al. 2013). Finally, human 
glioblastoma cells, human leukemia cells and human epidermal carcinoma cells were all 
arrested in the G0/G1 phase of the cell cycle (Chen et al. 2009; Chilampalli et al. 2011; 
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Fong et al. 2005). Of those studies reporting an increase in either p21 or p27, p21 
increased in human colon cancer cells, glioblastoma cells and epidermal carcinoma cells 
while p27 increased in human urinary bladder cancer cells and leukemia cells (Chen et al. 
2009; Chilampalli et al. 2011; Fong et al. 2005; Hsu et al. 2007; Lee et al. 2008a).
 At the time of writing only five papers are known to have been published 
regarding the effects of magnolol on prostate cancer, three of which comprise Chapters 
Two, Three and Four of this thesis. Of the remaining two papers, one focuses on the 
effects of magnolol on apoptosis in human prostate cancer cells while the other explores 
the anti-metastatic effects of magnolol on human prostate cancer cells. The apoptosis 
study focuses on the PC3 cell line, but includes cytotoxicity data from DU145 and 
LNCaP cells as well. Magnolol was found to be cytotoxic to all three cancerous prostate 
cell lines tested and induced apoptosis in PC3 human prostate cancer cells in vitro at a 
concentration of 60 µM magnolol after 8 h (Lee et al. 2009). Cellular signaling pathways 
were then tested to determine the mechanisms by which magnolol affected these cells and 
it was found that magnolol caused an increase in caspase-3 expression and decrease in p-
Akt and p-PI3K expression (Lee et al. 2009). This suggests that magnolol signals through 
the PI3K/Akt pathway in PC3 human prostate cancer cells. The metastasis study also 
focused on PC3 human prostate cancer cells exposed to 0-40 µM magnolol for 60 min to 
24 h time intervals (Hwang et al. 2010). It was found that magnolol decreased cellular 
proliferation of PC3 cells, as well as cellular adhesion and invasion in a dose-dependent 
manner (Hwang et al. 2010). Protein expression of the matrix metalloproteinases (MMP), 
specifically MMP-2 and MMP-9, were significantly reduced and wound-healing was 
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delayed (Hwang et al. 2010). This metastasis study showed that magnolol is capable of 
slowing the spread of PC3 human prostate cancer cells in vitro but makes note that the 
specific mechanisms by which this occurs remain unknown.
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1.2.2.2 Bioavailability, Delivery and Toxicity of Magnolol
When investigating a compound for its biological effects in vitro it is important to keep in 
mind the bioavailability and toxicity in vivo to ensure that concentrations investigated are 
appropriate and meaningful. In an overview of magnolol as a compound important to 
Chinese traditional medicine Chen et al. (2011) noted that magnolol has a “desirable 
spectrum of bioavailability” in that the compound is readily absorbed and is capable of 
crossing the blood-brain barrier. It is also noted that magnolol has historically been used 
at very high concentrations and for long term administration periods and toxicity has not 
been observed to occur (Chen et al. 2011). 
 Bioavailability studies performed in mouse and rat models have shown that, using 
two different methods of delivery, substantial concentrations of magnolol in the blood 
plasma could be achieved. Intravenous injection and oral administration have previously 
proven to be the most effective methods of delivery, with an injected dose of 2-10 mg/kg 
attaining a maximum blood plasma concentration of 10-40 µM magnolol while oral 
administration of 20 mg/kg could attain a maximum blood plasma concentration of 
0.1-0.4 µM magnolol (Ho and Hong 2012; Lin et al. 2011; Tsai et al. 1996). A third 
method of delivery, topical application, has been examined but this study found that 
while some absorption of magnolol into the skin occurred the concentrations would not 
likely be pharmacologically active with the maximal concentration achieved being 0.22 
nmol/mg (Lin et al. 2013). It was found that the elimination half-life for magnolol was 15 
min, with total body clearance at 72-75 ml/min/kg (Ho and Hong 2012; Homma et al. 
1993; Lin et al. 2011). After oral treatment magnolol has been observed to be retained in 
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the blood plasma for up to 1 h, with total recovery of magnolol in the urine being 16.7% 
of that administered (Ho and Hong 2012; Homma et al. 1993).
 In the study regarding the effects of magnolol on apoptosis in human prostate 
cancer cells mentioned above, both cancerous and non-cancerous cells were exposed to 
magnolol. While magnolol proved cytotoxic to the LNCaP, DU145 and PC3 human 
prostate cancer cell lines, non cancerous cells assayed showed little cytotoxicity in vitro 
(Lee et al. 2009). These non-cancerous cell lines included rat prostate endothelial cells 
(YPEN-1), immortalized nonmalignant human breast epithelial (MCF-10A) and a 
primary culture of human prostate epithelial cells (PrECs); these PrECs in particular 
showed the least cytotoxicity of all cells tested (Lee et al. 2009). Magnolol was also 
shown not to be mutagenic, and in fact to have anti-mutagenic effects, both in vitro and in 
vivo in a study which deemed magnolia bark extract safe for human dietary consumption 
(Lee et al. 2011; Li et al. 2007). Pre-clinical in vivo studies on the toxicity of magnolol 
have also been performed. These studies have shown that magnolol was non-toxic at 
every tested dose and that there were no drug related side effects nor alterations in 
immune response associated with magnolol exposure (Ho and Hong 2012; Li et al. 2007; 
Liu et al. 2007). The highest tested concentrations of these experiments were: 2.5 g/kg in 
mice, 0.48 g/kg/day for 21 days in rats and 0.24 g/kg/day for 90 days in rats (Ho and 
Hong 2012; Li et al. 2007; Liu et al. 2007). There was no meaningful change in kidney or 
thyroid weight, no dose-related difference in body weight or weight gain in any of the 
rats treated with magnolol and no meaningful change in blood or urine chemistry in any 
rats exposed to the highest tested dose of magnolol in these studies (Liu et al. 2007).
25
1.2.3 The Cell Cycle
For cells to multiply they must undergo a process of cellular division whereby the genetic 
material of the cell is duplicated, the cells grow in size and the cells divide into two 
identical daughter cells. For this kind of mitotic cellular division to occur cells must 
transition through the cell cycle, where each stage of the process is controlled. Cell 
division was originally divided into two different phases: mitosis (M) and interphase. 
This separation of cell division into two distinct phases was based on what was visibly 
happening in the cell, under a light microscope, during division: during mitosis 
chromosomes could be seen condensing, aligning themselves and separating, while 
during interphase the cells merely seemed to increase in size (Nasmyth 1996; Vermeulen 
et al. 2003). 
 The M phase is easily broken down based on what was visually occurring: in 
prophase the chromosomes become visible, in metaphase chromosomes align themselves 
across the middle of the cell, in anaphase the chromosomes separate to either pole of the 
cell, and in telophase chromosomes uncoil and are no longer visible. Upon the discovery 
that DNA synthesis occurred during a restricted portion of the interphase more 
investigation into interphase itself was warranted (Howard and Pelc 1951). The 
interphase was subsequently determined to consist of three different steps (Figure 1.2): 
G1, the first gap after mitosis where cells prepare for DNA synthesis; S, where DNA 
synthesis occurs; and G2, where cells prepare for mitosis (Nasmyth 1996; Vermeulen et 
al. 2003). Cells in G1 can also enter G0 before committing to DNA replication, where G0 
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is a resting state representing cells which are not actively growing or dividing (Vermeulen 
et al. 2003).
 Once these stages of interphase were discovered a major goal of cell cycle 
research became the investigation of factors triggering the transitions between G0, G1, S, 
G2 and M. The progression from G2 to M phase was found to be an M phase-promoting 
factor, and this M phase-promoting factor was further discovered to be a cyclin-
dependent protein kinase (CDK) (Nasmyth 1996). The CDKs are activated at different 
points of the cell cycle by shifting expression of the cyclins to progress the cell through 
the stages of the cell cycle (Vermeulen et al. 2003). The various actions of the cyclins and 
CDKs are as follows (Figure 1.2): cyclin D acts with CDK4 and CDK6 to progress the 
cell through the G1 phase, cyclin E acts in conjunction with CDK2 to transition from G1 
to S phase, cyclin A acts with CDK2 to progress the cell through the S phase and with 
CDK1 to transition from G2 to M phase, and cyclin B is involved with progression 
through the M phase of the cell cycle (Schwartz and Shah 2005; Vermeulen et al. 2003).
 CDK activity is also controlled by a series of CDK inhibitors which can prevent 
progression through the cell cycle. There are two important families of CDK inhibitors: 
the INK4 family and the Cip/Kip family. The INK4 family of CDK inhibitors consists of 
p16INK4a, p15INK4b, p18INK4c and p19INK4d. These INK4 proteins inhibit only G1 phase 
CDKs and cyclins, namely: CDK4, CDK6 and cyclin D as well as the complexes formed 
through interaction of these CDKs and cyclins (Johnson and Walker 1999; Vermeulen et 
al. 2003). The Cip/Kip family proteins consist of p21, p27 and p57. These proteins 
broadly inhibit activity of CDKs and cyclin/CDK complexes, particularly involving 
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cyclin D or cyclin B, but show inhibitory activity on complexes involving the other 
cyclins as well (Johnson and Walker 1999; Vermeulen et al. 2003). The Cip protein p21 is 
also directly involved in DNA synthesis and is under the control of p53, the tumor 
suppressor protein (Johnson and Walker 1999; Vermeulen et al. 2003).
 The final group of CDK inhibitory proteins important to this study are the RB 
proteins, pRBp107 and pRBp130. The RB proteins can bind to cyclin A/CDK2 and 
cyclin E/CDK2 complexes and inhibit their activity (Johnson and Walker 1999). The 
pRBp107 and pRBp130 proteins also bind to, and inhibit, proteins in the E2F family; 
these E2F proteins are involved in progression through the cell cycle by activating 
cyclins A and E (Johnson and Walker 1999; Mayol and Graña 1997).
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Figure 1.2: An overview of the cell cycle and the key regulatory proteins involved in cell 
cycle progression and arrest (Adapted from Vermeulen et al. 2003).
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1.2.3.1 Dysregulation of the Cell Cycle in Cancer
Mutations to cell cycle proteins are common in many different kinds of cancer and 
roughly 70% of human prostate cancers exhibit mutations involving proteins of the cell 
cycle (Malumbres and Barbacid 2001). The most common mutations of cell cycle 
proteins in human prostate cancer involve the RB proteins, cyclin D1, cyclin E1, p16INK4a 
and p27 (Malumbres and Barbacid 2001). Of these affected proteins the most commonly 
mutated cell cycle protein across many different cancers is cyclin D1 (Johnson and 
Walker 1999; Vermeulen et al. 2003). Alterations in cyclin D1 activity can lead to 
quiescent cells progressing through G1 and into S phase of the cell cycle. While the 
CDKs are rarely affected directly, alterations in CDK activity are common in many 
cancers as well due to CDK inhibitors being common sites of mutations in the 
development of cancer (Johnson and Walker 1999; Malumbres and Barbacid 2007, 2009; 
Vermeulen et al. 2003). This means that both CDKs themselves and CDK inhibitors are 
interesting targets for new anti-cancer drugs. One of the most well studied inhibitors of 
the cell cycle is the tumor suppressor protein p53. p53 acts through p21, meaning that a 
decrease in p53 activity would result in decreased p21 activity and therefore allow cell 
cycle progression to occur unmediated (Johnson and Walker 1999; Vermeulen et al. 
2003). Of the three human prostate cancer cell lines used in this study, only DU145 cells 
show significant expression of p53, at roughly 90% that of normal prostate cells, while 
LNCaP cells express roughly 10% that of normal cells and PC3 cells do not express p53 
at all (van Bokhoven et al. 2003).
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1.2.4 Polyamine Biosynthesis and Catabolism
Polyamines were first discovered in 1678 by Anthonii van Leeuwenhoek, but no 
chemical formula or structure was known until 1924 (Dudley et al. 1924; van 
Leeuwenhoek 1678; Wallace et al. 2003). The polyamines are putrescine (NH2(CH2)
4NH2), spermidine (NH2(CH2)3NH(CH2)4NH2) and spermine (NH2(CH2)3NH(CH2)4NH
(CH2)3NH2) with spermidine and spermine being the most abundant in eukaryotic cells 
(Igarashi and Kashiwagi 2009). Due to the gap between discovery and characterization 
the names of spermine and spermidine refer to the original site of discovery of these two 
compounds while the name of putrescine refers to the abundance of the compound found 
in putrefying flesh (Wallace et al. 2003). Historically, polyamines were thought of as 
intracellular growth factors, but polyamines have more recently been found to regulate 
apoptosis as well (Wallace et al. 2003). 
 Polyamines are found in nearly all living species and are essential for cellular 
growth and proliferation, cell differentiation and the avoidance of apoptosis (Wallace et 
al. 2003). The major function of polyamines lies in their ability to bind to and change the 
conformation of DNA, RNA, ATP and proteins (Thomas and Thomas 2003). Polyamines 
bind to RNA and in doing so cause conformational changes in the RNA leading to 
increased protein synthesis (Igarashi and Kashiwagi 2009). Similarly, polyamines can 
bind to and stimulate the assembly of the 30S subunit of ribosomes to further contribute 
to increased protein synthesis (Igarashi and Kashiwagi 2009). Although polyamines 
interact more weakly with DNA and ATP, they can also bind to these molecules. By 
binding to DNA, polyamines can again cause conformational changes resulting in 
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increased transcription (Thomas and Thomas 2003). Polyamine binding to ATP allows 
ATP to more easily phosphorylate protein kinases and thereby drives enzymatic reactions 
(Igarashi and Kashiwagi 2009).
 Polyamines have also been implicated in cellular signaling cascades, where 
decreased polyamine levels cause an increase in MAPK signaling which results in 
increased p21 expression and increased ornithine decarboxylase (ODC) expression 
(Thomas and Thomas 2003). This increase in ODC expression would then result in 
increased polyamine levels. Polyamines and ODC have also been shown to fluctuate 
during the cell cycle (Wallace et al. 2003). ODC expression and polyamine 
concentrations peak in G1, prior to entering the S phase, and both peak again in G2 prior 
to mitosis. The exact link between the polyamines and the cyclins/CDKs is unknown, but 
it is suspected that polyamines regulate cyclin degradation (Wallace et al. 2003). 
Polyamine content is tightly regulated by cells, maintaining the minimal concentration 
required for cell growth without inducing toxicity. Typically, polyamines are synthesized 
within the cell as needed, but polyamines can also be transported into and out of the cell 
to accommodate excess or deficiency (Wallace et al. 2003). 
 Polyamine biosynthesis (anabolism) and catabolism are controlled by a series of 
proteins summarized in Figure 1.3. Ornithine decarboxylase (ODC) is the rate limiting 
factor of polyamine biosynthesis, responsible for the conversion of ornithine to putrescine 
(Pegg 2006). ODC is itself regulated by antizyme (AZ) which is in turn regulated by 
antizyme inhibitor (AZI). AZ acts as a non-competitive inhibitor of ODC, where AZ and 
ODC will form a dimer which neutralizes ODC activity and increases the rate of ODC
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Figure 1.3: An overview of polyamine biosynthesis and catabolism and the key 
regulatory proteins and compounds involved (Copyright Scott McKeown 2014, used with 
permission).
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 degradation (Kahana 2009; Pegg 2006). AZI is structurally similar to ODC but lacks any 
ODC activity while being equally as effective at binding to AZ; AZI therefore 
functionally removes AZ from the system without decreasing ODC activity (Olsen and 
Zetter 2011; Pegg 2006). AZ is also capable of stimulating the transport of polyamines 
out of the cell and inhibits the transport of polyamines into the cell (Igarashi and 
Kashiwagi 2009).
 While ODC activity is the essential primary step in polyamine biosynthesis there 
are other key enzymes involved. Continuing on the polyamine biosynthetic pathway, S-
adenosylmethionine decarboxylase (SAMDC) is the rate limiting factor governing 
biosynthesis of spermidine from putrescine and of spermine from spermidine. SAMDC 
converts S-adenosylmethionine to decarboxylated S-adenosylmethionine which is then 
used by spermidine synthase and spermine synthase to synthesize spermidine and 
spermine, respectively (Shantz and Pegg 1999). In this way SAMDC controls spermidine 
and spermine production.
 In polyamine catabolism there are two key proteins involved, polyamine oxidase 
(PAO) and spermidine/spermine N1-acetyltransferase (SSAT), which act together to 
catabolize spermidine to spermine and spermine to putrescine. SSAT first acts to convert 
spermine to N1-acetylspermine then PAO completes the catabolic process by converting 
N1-acetylspermine to spermidine, this process is then repeated with SSAT converting 
spermidine to N1-acetylspermidine and PAO converting this to putrescine (Casero and 
Pegg 1993; Shantz and Pegg 1999). SSAT is generally held to be the rate limiting factor 
in polyamine catabolism (Casero and Pegg 1993).
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1.2.4.1 Dysregulation of Polyamine Biosynthesis and Catabolism
Polyamines are an obvious target for anti-cancer research due to their effects on cellular 
proliferation and the increased concentrations of polyamines in most types of cancer. 
Increased levels of polyamines have long been associated with many cancers, including 
prostate cancer, and often polyamine levels increase due to dysregulation of oncogenes 
and tumor suppressor genes (Nowotarski et al. 2013; Paz et al. 2014). It has been posited 
that polyamines themselves are a class of oncometabolites which are necessary for 
oncogenesis and that polyamine targeted therapy is a viable method of both 
chemoprevention and chemotherapy (Paz et al. 2014). Attempts at targeting the 
polyamine biosynthetic pathway have been made as early as 1972 when a SAMDC 
inhibitor was synthesized; these early attempts, however, proved unsuccessful as the 
compounds developed were toxic to many patients (Thomas and Thomas 2003; Williams-
Ashman and Schenone 1972). More recently ODC has been described as an oncogene 
due to its role in cellular proliferation and ODC activity has become the target of 
therapies seeking to lower polyamine concentrations in cancer cells (Olsen and Zetter 
2011).
 Increased ODC expression occurs in many different types of cancer, with ODC 
being regulated by androgens in the normal prostate gland leading to highly elevated 
ODC levels in androgen-independent prostate cancer (Olsen and Zetter 2011; Pegg 
2006). It has been found that, in vitro, ODC overexpression alone can lead to 
carcinogenesis and tumor formation and several ODC inhibitors are currently undergoing 
clinical trials for cancer treatment (Olsen and Zetter 2011). These clinical trials have not 
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been met with much success thus far, but the targeting of AZI in cancer therapy may also 
prove a sound strategy (Olsen and Zetter 2011). Increased AZI is associated with 
decreased patient survival and increased metastatic potential in several different types of 
cancer (Kahana 2009; Olsen and Zetter 2011). The disruption of AZI has been associated 
with inhibited ODC and decreased polyamine levels leading to a reduction in cellular 
growth and proliferation (Kahana 2009).
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1.2.5 Cellular Signaling Pathways
The cellular signaling pathways mediate cellular response to both external and internal 
stimuli. For the purpose of this thesis the phosphatidylinositol 3-kinase (PI3K), mitogen-
activated protein kinase (MAPK), nuclear factor kappa-light-chain-enhancer of activated 
B cells (NFκB) and activator protein-1 (AP-1) pathways will be focused upon.
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1.2.5.1 PI3K/Akt Signaling Pathway
The phosphatidylinositol 3-kinase (PI3K) pathway (Figure 1.4) first became a focus in 
cancer research when it was associated with the activity of viral oncogenes in 1985 
(Vivanco and Sawyers 2002; Whitman et al. 1985). In normal cells the PI3K pathway is 
an important regulator of cellular proliferation, growth, apoptosis and cytoskeletal 
rearrangement (Vivanco and Sawyers 2002). PI3K is a heterodimer consisting of 
PI3Kp85, the regulatory subunit, and PI3Kp110, the catalytic subunit; these PI3Kp85/
PI3Kp110 heterodimers typically exist pre-formed and inactive within the cell, awaiting 
signaling for activation (Vivanco and Sawyers 2003; Yuan and Cantley 2008). PI3K can 
be activated by either receptor tyrosine kinase (RTK) embedded in the cell membrane or 
by the RAS oncogene; this activation results in the PI3K mediated phosphorylation of 
phosphatidylinositol-4,5-biphosphate (PIP2) which converts it to 
phosphatidylinositol-3,4,5-triphosphate (PIP3) (Vivanco and Sawyers 2002; Yuan and 
Cantley 2008). PI3K activity is counteracted by the phosphatase and tensin homologue 
(PTEN) protein which converts PIP3 back to PIP2 and thereby acts as both an anti-
signaling and tumor-suppressor gene (Vivanco and Sawyers 2002). PIP3 then activates 
protein kinase B (Akt) which is in turn responsible for further signaling to the proteins 
responsible for proliferation, growth and apoptosis. Briefly, Akt is capable of activating 
IκB Kinase (IKK) and the mammalian target of rapamycin (mTOR) protein, which inhibit 
apoptosis and induce cellular growth respectively, and deactivating p53, p21, p27 and 
glycogen synthase kinase-3β (GSK3β) which results in the induction of cellular 
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Figure 1.4: An overview of the PI3K/Akt signaling pathway and the key proteins 
involved (Copyright Scott McKeown 2014, used with permission).
39
proliferation (Fresno Vara et al. 2004; Vivanco and Sawyers 2002). In leukemia cells the 
PI3K pathway has also been shown to lead to ODC activation (Flamigni et al. 1997).
 In cancerous cells mutations of the PI3K pathway are common at every stage in 
the pathway and mutations of PI3K genes are found in a broad range of cancers (Fresno 
Vara et al. 2004; Vivanco and Sawyers 2002; Yuan and Cantley 2008). The most common 
alteration to PI3K proteins is typically amplification, particularly in the case of PI3Kp110 
and Akt (Fresno Vara et al. 2004). The exception to this is PTEN which is commonly 
deleted or mutated in such a way as to become non-functional. Loss of PTEN activity is 
common in human cancers, particularly in human prostate cancer (Liu et al. 2014). Of the 
three cell lines commonly used in prostate cancer research DU145 cells show normal, 
unmodified PTEN while LNCaP cells exhibit a mutated and less functional PTEN and 
PC3 cells are PTEN deficient (Vlietstra et al. 1998). Recent studies have shown that 
compounds which target PI3K to reduce its activity can induce cell cycle arrest (Liu et al. 
2014).
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1.2.5.2 MAPK Signaling Pathways
The mitogen-activated protein kinase (MAPK) pathways (Figure 1.5) consist of three 
major branches: the extracellular signal-regulated kinase (ERK) pathway, the c-Jun N-
terminal kinase (JNK) pathway and the p38 pathway. These three MAPK pathways are 
involved in signaling for cellular growth, differentiation and death, and are widespread 
cellular signaling mechanisms common in the regulation of all eukaryotic cells (Krishna 
and Narang 2008). There are several features shared by the MAPKs, leading to them 
commonly being grouped together: the three pathways share a three tiered signaling 
mechanism whereby mitogen-activated protein kinase kinase kinases (MAP3Ks) are 
activated in response to extracellular stimuli, these MAP3Ks then activate mitogen-
activated protein kinase kinases (MAP2Ks) which in turn activate the three MAPK 
pathways and their subsequent downstream targets (Krishna and Narang 2008).
 The first MAPK described was ERK, as a protein involved in cell cycle control in 
yeast, which is expressed in all tissues of the human body and plays an important role in 
cellular proliferation and apoptosis (Boulton et al. 1990; Krishna and Narang 2008). ERK 
signaling begins with RTK and/or G protein-coupled receptors (GPCRs) responding to 
extracellular stimuli and activating G proteins such as RAS which in turn activate the 
MAP3K tier proteins like Raf kinases (Krishna and Narang 2008). These MAP3K 
proteins then activate the MAP2K tier proteins mitogen-activated protein kinase/
extracellular signal-regulated kinase kinase (MEK)-1 and MEK-2 which in turn activate 
ERK-1 and ERK-2, two isoforms of ERK (Krishna and Narang 2008). Downstream 
targets of ERK include c-jun, c-fos and various proteins involved in cellular proliferation 
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Figure 1.5: An overview of the MAPK signaling pathway and the key proteins involved 
(Copyright Scott McKeown 2014, used with permission).
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and apoptosis (Krishna and Narang 2008). ERK dysregulation occurs in approximately 
1/3 of all human cancers, where amplified ERK signaling leads to increased cellular 
proliferation, angiogenesis and metastasis (Krishna and Narang 2008). Increased 
expression of ERK has also been linked to increased ODC expression in human tissue 
cultures (Flamigni et al. 1999, 2001).
 JNK was the second MAPK to be identified, originally known as stress activated 
protein kinase (SAPK) when first purified in rats, its name was later changed to JNK to 
better reflect its activity (Krishna and Narang 2008; Kyriakis and Avruch 1990). Like 
ERK, JNK exists in two different isoforms: JNK-1 and JNK-2. The JNK pathway is 
initially activated by a wide variety of external stimuli which in turn activate various 
MAP3Ks. These MAP3Ks then activate mitogen-activated protein kinase kinase 
(MKK)-4 and MKK-7 which in turn activate JNK-1 and JNK-2 (Krishna and Narang 
2008). The major target of JNK is the activation of AP-1 through c-jun activation, 
although JNK can also inhibit p53, inhibit apoptosis and inhibit cellular proliferation 
(Krishna and Narang 2008; Wagner and Nebreda 2009; Weston and Davis 2007). JNK 
expression is greatly increased in several types of cancer, including prostate cancer 
(Krishna and Narang 2008; Wagner and Nebreda 2009; Weston and Davis 2007). JNK is 
capable of destabilizing p53, leading to its degradation, and loss of c-jun associated with 
decreased JNK signaling has been correlated with reduced tumor size and improved 
prognosis (Krishna and Narang 2008).
 The effects of the third MAPK, p38, appear to be antagonistic to JNK, with the 
two MAPKs being intricately linked and acting in opposition (Wagner and Nebreda 
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2009). p38 was first identified as a 38 kDa protein rapidly phosphorylated in response to 
lipopolysaccharide exposure in a mouse cell line (Han et al. 1993; Ono and Han 2000). 
p38 is involved in osmoregulation, extracellular stress response and the cell cycle 
(Krishna and Narang 2008). Activation of p38 occurs by the same routes as JNK 
activation, with the same stimuli activation both JNK and p38 (Krishna and Narang 2008; 
Weston and Davis 2007). Separate from JNK, IGF can begin the MAP3K cascade toward 
p38 activation and there are two MAP2Ks, MKK-3 and MKK-6, which activate p38 
(Krishna and Narang 2008). p38 can activate p53 and inhibitors of the cell cycle as well 
as downregulate cyclins, activate apoptosis and activate the NFκB p65 protein (Krishna 
and Narang 2008; Ono and Han 2000; Wagner and Nebreda 2009). There is also evidence 
to suggest that p38 can inhibit JNK signaling and that increased p38 is linked to 
decreased ODC expression (Flamigni et al. 2001; Wagner and Nebreda 2009). These 
factors support p38 as a tumor suppressor, with overexpression of p38 resulting in slowed 
cellular proliferation, and it has been suggested that p38 is necessary for induction of 
apoptosis (Krishna and Narang 2008).
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1.2.5.3 NFκB and AP-1 Signaling Pathways
The final two signaling pathways discussed in this thesis are nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) (Figure 1.6) and activator protein-1 (AP-1) 
(Figure 1.7). These two pathways act as transcription factors and migrate from the 
cytoplasm to the nucleus where they bind directly to DNA and influence protein 
expression (Fujioka et al. 2004). NFκB and AP-1 have been linked in that they are 
generally activated simultaneously and act in a cooperative manner (Fujioka et al. 2004).
 NFκB was originally described coincidently by two independent research groups, 
one describing the NFκB subfamily of proteins which they identified in human HeLa 
cells and the other describing the reticuloendotheliosis (Rel) subfamily of proteins 
identified in chicken embryo fibroblasts (Gilmore 2006; Gilmore and Temin 1986; Sen 
and Baltimore 1986). The NFκB proteins were named after the κB site of DNA to which 
they bind (Gilmore 2006). The NFκB proteins are divided into these two subfamilies 
which form heterodimers using their shared Rel homology domain (RHD) (Gilmore 
2006). The proteins of the NFκB subfamily are p50/p105 (NFκB1) and p52/p100 
(NFκB2). The proteins of the Rel subfamily are NFκBp65 (RelA), RelB and c-Rel; these 
are the subunits responsible for activating transcription, with NFκBp65 being an 
important biomarker for human prostate cancer (Gannon et al. 2013; Gilmore 2006; 
Karin et al. 2002). NFκB proteins signal for the transcription of cyclin D, cyclin E, 
CDK2, MMPs, c-fos and other proteins involved in angiogenesis and apoptosis 
avoidance (Bassères and Baldwin 2006; Fujioka et al. 2004; Karin et al. 2002). NFκB is 
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Figure 1.6: An overview of the NFκB signaling pathway and the key proteins involved 
(Copyright Scott McKeown 2014, used with permission).
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Figure 1.7: An overview of the AP-1 signaling pathway and the key proteins involved 
(Copyright Scott McKeown 2014, used with permission).
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generally present in cells in its dimerized form, but is kept inactive by inhibitor of κB 
(IκB) proteins which recognize the RHD shared by NFκB proteins and bind to it, thereby 
blocking NFκB activity as the RHD is also used to bind DNA (Gilmore 2006; Karin et al. 
2002). The most common of these IκBs is inhibitor of κB α (IκBα), which has the most 
universal ability to bind any NFκB protein (Gilmore 2006). IκB is in turn controlled by 
IκB Kinase (IKK) which degrades IκB and allows NFκB dimers to enter the nucleus and 
activate gene expression (Gilmore 2006). As NFκB dimers are common, in an inactive 
state due to IκB, it is IKK which generally initiates NFκB signaling. In normal cells, 
NFκB shows negative feedback by also increasing expression of IκBα (Gilmore 2006; 
Karin et al. 2002).
 The AP-1 complex was first described by Lee et al. (1987) who were 
investigating eukaryotic transcription promotors. AP-1 proteins are divided among four 
subfamilies (jun, fos, mef and ATF) which form dimers to create the active AP-1 complex 
(Shaulian and Karin 2002). Of these four the jun and fos subfamilies are the most 
prevalent, with c-jun and c-fos being the most important proteins in each family 
(Shaulian and Karin 2001, 2002). The AP-1 transcription factor is generally activated by 
external stimuli and subsequent signaling through the MAPK pathway, with c-jun being 
the major target of JNK (Shaulian 2010; Shaulian and Karin 2002). AP-1 activates 
cycling D expression and inhibits the expression of p53, p21 and p16INK4a (Shaulian and 
Karin 2001, 2002). In cancer cells c-jun and c-fos overexpression is common, both being 
considered important oncoproteins, due to their role in transcription (Shaulian 2010; 
Shaulian and Karin 2001, 2002; Vesely et al. 2009). The role of AP-1 in apoptosis is more 
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complex, with AP-1 being capable of both induction and inhibition of apoptosis (Shaulian 
and Karin 2002). While the effect of AP-1 on apoptosis appears to be highly tissue 
specific, it is still not well understood.
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1.2.6 Insulin-Like Growth Factors and Binding Proteins
Growth factors, such as insulin-like growth factor (IGF), cause cells to grow and divide 
much as their name would imply. The IGF proteins were independently discovered by 
two separate research groups, one studying mitogenic properties of proteins and the other 
studying metabolic functions. The first publication naming IGF was published in 1978, 
but research on the IGF proteins began several years prior (Rinderknecht and Humbel 
1978). The first group to report on these proteins named them the somatomedins, 
describing their mitogenic function and ability to promote sulfate uptake in cartilage 
(Daughaday et al. 1972; Hall 1972; Van Wyk et al. 1974). Of these proteins described, 
the most promising were somatomedin A and somatomedin C which were both controlled 
by growth hormone (GH) (Hall 1972; Van Wyk et al. 1974). The other research group, 
investigating growth and metabolism promoting proteins, described the non-suppressible 
insulin-like activity (NSILA) proteins in human serum (Zapf et al. 1978). When a 
NSILA protein was discovered to have structural homology with insulin it was re-named 
insulin-like growth factor (Humbel 1990; Rinderknecht and Humbel 1978; Russell et al. 
1998). Finally, both somatomedin A and C were found to be structurally identical to IGF-
I (Engberg et al. 1984; Klapper et al. 1983).
 There are two different IGF proteins, IGF-I and IGF-II, which primarily act at 
different stages in development (Yu and Rohan 2000). IGF-I is generally produced in the 
liver in healthy individuals, but can also be produced in most other tissues of the body 
(Pollak 2008). IGF-I is capable of regulating cellular proliferation and apoptosis in 
relation to the diet by stimulating protein synthesis and increasing metabolism (Harvey et 
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al. 2013; Pollak et al. 2004; You et al. 2002; Yu and Rohan 2000). Generally, IGF-I levels 
increase from birth and reach their peak expression at puberty, with a general decline in 
IGF-I thereafter (Yu and Rohan 2000). This rise and fall of IGF-I concentration is 
primarily controlled by GH (Yu and Rohan 2000). IGF-II is key to embryonic and fetal 
development, but is gradually replaced by IGF-I after birth; despite this, IGF-II is present 
in higher concentrations than IGF-I in adults with IGF-I being considered the more 
important governor of post-natal growth (Yu and Rohan 2000).
 The IGFs signal (Figure 1.8) by binding to insulin-like growth factor receptors 
(IGF-R) in the cell membrane (Pollak 2008; Pollak et al. 2004; Yu and Rohan 2000). As 
with the IGFs there are two IGF-Rs, IGF-IR and IGF-IIR, which serve different functions 
in IGF signaling. IGF-IIR, which only IGF-II binds to, has no function in IGF signaling 
and simply serves to remove IGF-II from the system by degradation (Pollak 2008; Yu and 
Rohan 2000). IGF-IR is central to IGF signaling, binding both IGF-I and IGF-II, as it is 
expressed in all normal tissues and serves to begin IGF-mediated signaling within the cell 
(Pollak 2008; Yu and Rohan 2000). IGF-IR then activates the insulin-receptor substrate 
(IRS) which goes on to activate the PI3K and MAPK signaling pathways (Pollak et al. 
2004). As mentioned previously, IGF-I expression can be tied to diet, with caloric 
restriction having been shown to cause a decrease in IGF-I expression (Harvey et al. 
2013; Pollak et al. 2004). This decreased IGF-I has been linked, through PI3K signaling, 
to a resulting decrease in NF-κBp65 expression and therefore reduced NFκB signaling 
(Harvey et al. 2013).
51
Figure 1.8 An overview of the IGF signaling pathway and the key proteins involved in its 
regulation (Copyright Scott McKeown 2014, used with permission).
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 Upstearm of IGF signaling are the six insulin-like growth factor binding proteins 
(IGFBPs). The IGFBPs were originally discovered while trying to purify IGF-I from 
serum, with the names of the IGFBPs reflecting the order in which they were discovered 
(Brown et al. 1989; Clemmons 1997; Drop et al. 1984; Hintz and Liu 1977; Martin and 
Baxter 1986; Póvoa et al. 1984; Shimasaki et al. 1991; Zapf et al. 1975). The IGFBPs 
function in binding to IGF before it can bind to IGF-IR. This serves to both stabilize IGF 
by slowing degradation as well as to functionally remove IGF from the system while the 
proteins remain bound together. IGF bioactivity can be decreased by increased expression 
of certain IGFBPs which are in turn activated by p53 (Pollak 2008). IGFBP-1 expression 
is typically limited to the liver, in low concentrations, and delivered to various tissues 
where it inhibits IGF-I by blocking interaction with IGF-IR (Clemmons 1997). IGFBP-2 
through IGFBP-5 are commonly expressed in most cells at various concentration and are 
the most functionally important IGFBPs (Clemmons 1997).  IGFBP-2 is the second most 
abundant IGFBP in serum, enhancing the effect of IGF-I (Clemmons 1997). There is also 
evidence of IGFBP-2 showing IGF-independent activity involved in the induction of 
mitosis (Firth and Baxter 2002). IGFBP-3 is the most common IGFBP and the principle 
carrier of IGF-I in serum, having one of the highest affinities for IGF-I (Clemmons 
1997). Due to this high binding affinity IGFBP-3 inhibits IGF signaling by remaining 
bound to IGF-I; this tendency of IGFBP-3 to remain bound to IGF-I does, however, 
increase IGF-I half-life (Clemmons 1997; Massoner et al. 2009). Independent of IGF, 
IGFBP-3 can also directly inhibit DNA synthesis and cellular adhesion(Clemmons 1997). 
MMP-1 and MMP-2 have been known to degrade IGFBP-3 (Clemmons 1997; Massoner 
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et al. 2009). IGFBP-4 is the only IGFBP which exclusively inhibits IGF-I, resulting in 
decreased cell growth (Clemmons 1997; Durai et al. 2006). IGFBP-5, like IGFBP-2, 
stimulates IGF action and is commonly expressed in most cells (Clemmons 1997). The 
stimulation of IGF action happens due to a high affinity for IGFBP-5 to bind IGF-I in 
serum and a dramatic lowering of that binding affinity when IGFBP-5 binds to the  
extracellular matrix, resulting in the release of IGF-I nearby IGF-IR bound to the cell 
membrane (Clemmons 1997). IGFBP-5 can also induce mitosis and inhibit apoptosis 
independently of IGF (Cobb et al. 2004; Firth and Baxter 2002). Finally, IGFBP-6 is 
expressed in low concentrations, primarily by cells surrounding cartilage, and appears to 
primarily inhibit IGF-II, although some inhibition of IGF-I has been suggested 
(Clemmons 1997).
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1.2.6.1 Dysregulation of Insulin-Like Growth Factors and Binding Proteins in 
Cancer
In cancerous cells IGF-I commonly becomes overexpressed, regardless of the tissue of 
neoplastic origin (Pollak 2008). For example, in a non-diseased state only stromal cells of 
the prostate will produce IGF, but cancerous prostate cells of any origin will overexpress 
IGF-I (Russell et al. 1998). IGF overexpression has been implicated with activation of 
many oncogenes, and drugs targeting IGF-I have been explored for their anti-cancer 
activity (Pollak 2008; Yu and Rohan 2000). High levels of IGF-I are frequently observed 
in prostate, breast and colorectal cancers and increased IGF-I is considered a risk factor 
for these diseases (Pollak 2008; Saikali et al. 2008; Yu and Rohan 2000). DU145, PC3 
and LNCaP cells are all known to overexpress IGF-I (Russell et al. 1998). In DU145 cells 
addition of IGF-I to media was shown to increase cellular invasion through increased 
expression of MMP-2 and MMP-9, which was activated through the PI3K and MAPK 
pathways (Saikali et al. 2008). As with IGF-I, IGF-IR is also commonly overexpressed 
by human cancers, thus increasing signaling and activation of the PI3K and MAPK 
pathways; IGF-IIR, however, will act as a tumor suppressor by binding IGF-I without any 
associated signaling (Pollak 2008). Decreasing the expression of IGF-IR has also been 
shown to decrease cellular invasion in PC3 human prostate cancer cells (Saikali et al. 
2008). Overexpression of IGF-IR is typical of aggressive tumors, with loss of PTEN 
having the capacity to cause excessive IGF-IR signaling (Pollak et al. 2004; Yu and 
Rohan 2000). IGF-IR expression can be suppressed by p53, suggesting that loss of p53 in 
cancerous cells contributes to increased IGF signaling (Yu and Rohan 2000).
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 The IGFBPs are also important in the development and regulation of cancerous 
cells. In prostate cancer cells increased expression of IGFBP-2 and IGFBP-5 is typical, as 
is decreased expression of IGFBP-3 (Yu and Rohan 2000). In PC3 and LNCaP cells, 
IGFBP-4 is also underexpressed (Russell et al. 1998). MMPs appear to be capable of 
degrading IGFBPs, resulting in the release of bound IGF-I (Pollak et al. 2004). Increased 
levels of IGFBP-2 are broadly found in prostate cancer, and increasing expression of 
IGFBP-2 has been associated with the progression toward androgen insensitivity 
(DeGraff et al. 2009). IGFBP-3 expression is typically decreased, and increased 
expression of IGFBP-3 has been shown to inhibit metastasis in mouse models of prostate 
cancer (Mehta et al. 2011). As p53 can induce IGFBP-3, this reduction of IGFBP-3 is 
associated with decreased p53 expression (Yu and Rohan 2000).
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CHAPTER TWO
Magnolol Causes Alterations in the Cell Cycle in Androgen Insensitive Human 
Prostate Cancer Cells In Vitro by Affecting Expression of Key Cell Cycle Regulatory 
Proteins1
2.1 Introduction
Cancer is the second leading cause of death worldwide, with prostate cancer being the 
second most commonly diagnosed form in men (ACS 2011). A suggested approach in 
treating prostate cancer is to monitor the disease but not administer treatment until after 
symptoms have appeared due to the noncurative nature of treatment and associated side 
effects (Miyake et al. 2000; Raghavan et al. 1997). As a result, there has been an 
increasing amount of research interest in natural products and their bioactive effects, 
many of which have been used in traditional herbal medicine (Bemis et al. 2006; Ikarashi 
et al. 2001; Zhang et al. 2005). Magnolol is a lignan found in the roots and bark of the 
magnolia tree Magnolia officinalis and has been shown to have anti-cancer effects in 
human cells in vitro and in vivo (Chuang et al. 2011; Hsu et al. 2007; Hwang and Park 
2010; Kim et al. 2007; Lee et al. 2009; Lee et al. 2008a; Lin et al. 2001; Lin et al. 2002; 
Rasul et al. 2012). In plants, lignans typically function as deterrents to pests, providing 
defense against insects by interfering with hormonal signaling (Harmatha and Dinan 
2003; Lee and Xiao 2003). Lignans have also gained attention for their potential anti-
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1 The results of this study have been previously published in the journal Nutrition and 
Cancer (McKeown et al. 2014). This chapter is an adaptation and reformatting of that 
publication.
cancer and anti-viral effects, in both the plants which produce them and animals which 
consume them (Lee and Xiao 2003). Those studies performed in vivo suggest that 
magnolol remains active when administered at a sufficient oral dosage. Preclinical studies 
on the bioavailability of magnolol have previously been performed in mouse and rat 
models. Two methods of delivery were used in these previous studies, intravenous 
injection and oral administration. Of these two delivery methods it was found that an 
injected dose of 2-10 mg/kg could attain a maximum blood plasma concentration of 10 
µg/ml or 40 µM magnolol, whereas oral administration at 20 mg/kg could attain a 
maximum blood plasma concentration of 0.1 µg/ml or 0.4 µM magnolol (Ho and Hong 
2012; Lin et al. 2011; Tsai et al. 1996). The elimination half-life for magnolol was 
determined to be 15 min, with total body clearance at 72-75 ml/min/kg (Ho and Hong 
2012; Homma et al. 1993; Lin et al. 2011). Preclinical studies on the toxicity of magnolol 
have also previously been performed, showing that magnolol was nontoxic and that no 
drug-related side effects nor alterations in immune response were observed at any dose 
including the highest tested concentration of 2.5 g/kg in mice, 0.48 g/kg/day for 21 days 
in rats or 0.24 g/kg/day for 90 days in rats (Ho and Hong 2012; Li et al. 2007; Liu et al. 
2007). A clinical study has also shown that after oral treatment with a magnolol-
containing herbal medicine, magnolol was retained in the blood plasma for up to 1 h; 
furthermore the total recovery of magnolol in urine was 16.7% of that administered after 
24 h (Ho and Hong 2012; Homma et al. 1993). In the present study, the in vitro effect of 
magnolol on the cell cycle and related activities in DU145 and PC3 human prostate 
cancer cells was examined. This is novel research as the effects of magnolol on the cell 
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cycle in human prostate cancer cells have not previously been investigated. This study 
also represents the first evidence that magnolol can affect the expression of inhibitors of 
the cell cycle leading to cell cycle effects at later time points.
2.2 Materials and Methods
All antibodies used in this study were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). These include mouse polyclonal anti-actin and anti-p16INK4a, and 
rabbit polyclonal anti-cyclin A, anti-cyclin B1, anti-cyclin D1, anti-cyclin E, anti-CDK2, 
anti-CDK4, anti-p21, anti-p27, anti-pRBp107 and anti-pRBp130. Magnolol was 
purchased from Sigma-Aldrich Canada (Oakville, ON). All other chemicals and materials 
were purchased from Sigma-Aldrich Canada unless otherwise indicated.
2.2.1 Cell Culture and Treatment with Magnolol
Human DU145 and PC3 prostate adenocarcinoma cells (ATCC, Manasses, VA) were 
cultured on 100 mm plastic tissue-culture dishes (Falcon, Mississauga, ON) in α-MEM 
and RPMI (Gibco, Burlington, ON), respectively, supplemented with 10% fetal bovine 
serum (FBS) and 1% antibiotic-antimycotic (Invitrogen Canada, Burlington, ON), and 
were incubated at 37 0C. in 5% CO2. At 70% confluence, cells were exposed to either 40 
or 80 µM concentrations of magnolol, dissolved in dimethyl sulfoxide (DMSO), for 24 h 
or 6 h [concentration of DMSO in both magnolol-treated and control cells was 0.2% (v/
v)]. Control cells received only DMSO. After treatment, cells were removed using trypsin 
diluted in phosphate buffered saline (PBS) and re-suspended in α-MEM with 10% FBS 
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and centrifuged for 5 min at 500x G. The medium was then removed by aspiration. The 
remaining cell pellet was resuspended and washed in cold PBS. Cells were again 
centrifuged for 5 min at 500x G. After centrifugation, the PBS was removed by aspiration 
and the pellet was then stored at -80 0C until further analysis.
2.2.2 Immunoblot Analysis
Cell pellets were resuspended in 100 µl of 10 mM Tris-HCl buffer (pH 7.4) containing 
0.5 mM PMSF, and briefly sonicated. Cell lysates were then centrifuged at 9300x G for 
20 min at 4 0C. The supernatant was removed from the pellet and evaluated for protein 
content. Equal amounts of protein from this extract were mixed in a 3:1 ratio with 
standard Laemmli buffer consisting of 50 mM Tris-HCl (pH 6.8), 10% SDS, 0.1% 
bromophenol blue, 10% glycerol and 100 mM β-mercaptoethanol and then the samples 
were boiled for 3 min. Electrophoresis through 10% SDS-PAGE gels was used to resolve 
proteins which were then transferred onto nitrocellulose membranes (Bio-Rad, 
Mississauga, ON) by electro-blotting. Membranes were then incubated in the presence of 
a 1% BSA (w/v) TBS-Tween (0.05% v/v) solution overnight at 4 0C. Primary antibodies 
diluted to 1:200 (v/v) were then applied to membranes and incubated for 1 h at room 
temperature. After incubation, the membranes were washed 3 times with TBS-Tween 
(0.05% v/v) for a total of 30 min and then incubated with alkaline phosphatase (AP)-
conjugated secondary antibodies (1:1000) for 1.25 h at room temperature. After 
incubation the membranes were again washed 3 times with TBS-Tween (0.05%) for a 
total of 30 min and rinsed quickly with distilled water, then exposed to SigmaFast BCIP-
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NBT tablets (Sigma-Aldrich, Oakville, ON) dissolved in distilled water to visualize 
protein expression levels. Western blots were then photographed using Infinity Capture 
Software (Lumenera Corp., Ottawa, ON) and densitometry was performed with ImageJ 
Software (National Institute of Health, Bethesda, MD).
2.2.3 Alamar Blue Cytotoxicity Assay
Cellular viability after exposure to magnolol at 40 and 80 µM for 6 and 24 h was 
determined using the Alamar Blue assay (Invitrogen Canada) as per manufacturer’s 
instruction. The Alamar Blue assay measures cellular viability through the indicator 
resazurin. Resazurin, a blue compound which is nonfluorescent, is reduced to resorufin, a 
pink compound which is highly fluorescent, by the metabolic activity of viable cells 
(O’Brien et al. 2000). Alamar Blue is advantageous to use because it is a nontoxic 
alternative to the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) 
cytotoxicity assay (O’Brien et al. 2000).
 Briefly, cells were subcultured into a 96-well plate (Falcon) at approximately 
5000 cells/well. After 24 h incubation at 37 0C in 5% CO2, the cells were treated with 
magnolol for either 6 or 24 h. The control for this experiment consisted of cells treated 
with DMSO only [concentration of DMSO in magnolol-treated and control cells was 
0.2% (v/v)]. A negative control consisting of wells containing media only (no cells, no 
magnolol and no DMSO) was also evaluated. Alamar Blue was added to each well, to a 
final concentration of 10%, 3 h prior to fluorescence measurement which allowed for 3 h 
61
of exposure to Alamar Blue. After exposure to Alamar Blue, fluorescence was read with 
an excitation wavelength of 528 nm and an emission wavelength of 590 nm.
2.2.4 Flow Cytometry
Flow cytometric analysis was performed on cells treated with 40 and 80 µM magnolol for 
24 h and control cells treated with DMSO only [concentration of DMSO in both 
magnolol-treated cells and control cells was 0.2% (v/v)]. Flow cytometry can be used to 
measure cellular DNA content (Nunez 2001). To accomplish this, propidium iodide is 
used to stain DNA. The propidium iodide bound to DNA will fluoresce, and this 
fluorescence can be measured to determine DNA content (Nunez 2001). The flow 
cytometer will measure the cells within a sample and graph the recorded fluorescence 
from each of the cells individucally (Nunez 2001). This graph representing the DNA 
content of every individual cell within the sample can then be used to identify the 
proportion of cells in the various phases of the cell cycle (Nunez 2001). A peak 
representing cells which have unpaired DNA shows the percentage of cells in the G0/G1-
phase of the cell cycle (Nunez 2001). A separate peak representing cells cells which have 
paired DNA shows the percentage of cells in the G2/M-phase of the cell cycle (Nunez 
2001). Finally, cells which do not fall into either of these categories, fluorescing 
somewhere between the peaks characteristic of unpaired and paired DNA, are 
representative of the percentage of cells in the S-phase of the cell cycle (Nunez 2001).
 Cells were cultured and centrifuged as described above and placed in 225 µl of 
70:30 ethanol:PBS and incubated on ice overnight. “Fixed” cells were then centrifuged 
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for 5 min at 200x G at 4 0C, and were resuspended in 250 µl of ice-cold PBS and then 
incubated for 5 min. Cells were then centrifuged for 5 min at 200x G at 4 0C and the cell 
pellet was suspended in a PBS-propidium iodide [at a concentration of 0.02 mg/ml (w/
v))]staining solution containing Triton-X [at a concentration of 0.088% (v/v)] and 0.4 mg/
ml of RNAse and incubated for 30 min at room temperature in the dark. After incubation 
the cells were transferred to a round bottom 96-well plate (Falcon), and fluorescence 
measured using a BD FACSARRAY bioanalyzer equipped with BD FACSARRAY 
system software version 1.0.3 (BD Biosciences, Mississauga, ON). Analysis was 
performed using WinMDI software version 2.9 (Scripps Reseach Institute, La Jolla, CA).
2.2.5 Statistical Analysis
Statistical analysis was conducted using GraphPad Prism 4.03 for Windows (GraphPad 
Software, Inc. San Diago, CA). Results of immunoblot analyses and cytotoxicity assay 
were compared using a 1-way analysis of variance (ANOVA) with a Tukey’s post hoc test 
and results were considered statistically significant at P ≤ 0.05.
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2.3 Results
2.3.1 Magnolol Induced Cytotoxicity
The effect of magnolol on DU145 and PC3 human prostate cancer cells was measured 
using the Alamar Blue cytotoxicity assay. Viability of DU145 cells decreased 
significantly at both 40 and 80 µM after 6 and 24 h (Figure 2.1). In DU145 cells, viability 
decreased by 30% and 60% at 40 and 80 µM respectively after 6 h of exposure to 
magnolol and by 49% and 76% at 40 and 80 µM respectively after 24 h exposure to 
magnolol. Viability of PC3 cells also decreased at 80 µM after 6 and 24 h, decreasing to 
50% and 48%, respectively (Figure 2.1).  No statistically significant change in PC3 
viability was observed at 40 µM magnolol at either time point.
2.3.2 Magnolol Affects Cell Cycle Progression
Flow cytometric analysis was performed to determine if magnolol affects cell cycle 
progression by measuring the proportion of cells at each stage of the cell cycle. As shown 
in Figures 2.2, 2.3 and 2.4, DU145 and PC3 cells exposed to 40 and 80 µM magnolol for 
24 h show alterations in the cell cycle, with an increased number of cells at G0/G1-phase 
and a decreased number of cells at S and G2/M-phases. In control DU145 cells 42%, 36% 
and 22% of cells were in the G0/G1, S and G2/M-phase of the cell cycle, respectively. 
DU145 cells exposed to 40 µM magnolol exhibited 50%, 29% and 21% distribution 
between the G0/G1, S and G2/M-phase of the cell cycle, respectively. Finally, DU145 cells 
exposed to 80 µM magnolol exhibited 50%, 33% and 17% distribution between the
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Figure 2.1: Magnolol is cytotoxic to DU145 (A) and PC3 (B) cells in vitro. Cells were 
treated with either DMSO (Ctrl) or 40 or 80 µM magnolol in DMSO for either 6 or 24 h 
and cytotoxicity was determined by Alamar Blue assay. Fluorescence was read at 528 nm 
(excitation) and 590 nm (emission) wavelengths. Control cells were set to 100% viability. 
(C) Bar graph representing and comparing the data presented in figures A and B, where 
the first column of each group represents control, the middle column represents 40 µM 
and the final column represents 80 µM magnolol in DMSO. All experiments were 
performed with 6 replications using separate samples. (*) indicates P ≤ 0.05.
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C
Figure 2.2: Magnolol causes alterations in the cell cycle in DU145 cells in vitro. Figure 
2.2A, B and C are representative of flow cytometric analysis performed on DU145 cells 
treated with either DMSO (Ctrl), 40 or 80 µM magnolol in DMSO, respectively.
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Figure 2.3: Magnolol causes alterations in the cell cycle in PC3 cells in vitro. Figure 
2.3A, B and C are representative of flow cytometric analysis performed on PC3 cells 
treated with either DMSO (Ctrl), 40 or 80 µM magnolol in DMSO, respectively.
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Figure 2.4: Bar Graphs indicating the results of cell cycle analysis performed on DU145 
(A) and PC3 (B) cells at concentrations of magnolol indicated. These histograms 
summarize information presented in Figures 2.2 and 2.3. DU145 data (A) represents the 
average of two experiments, while PC3 data (B) represents the results of a single 
experiment. As such, no statistical analysis was performed.
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G0/G1, S and G2/M-phase of the cell cycle, respectively. In control PC3 cells 53%, 17% 
and 30% of cells were in the G0/G1, S and G2/M-phase of the cell cycle, respectively. PC3 
cells exposed to 40 µM magnolol exhibited 55%, 15% and 30% distribution between the 
G0/G1, S and G2/M-phase of the cell cycle, respectively. Finally, PC3 cells exposed to 80 
µM magnolol exhibited 63%, 11% and 26% distribution between the G0/G1, S and G2/M-
phase of the cell cycle, respectively.
2.3.3 Magnolol Affects Cell Cycle Protein Expression
In DU145 cells (Figure 2.5) the expression of CDK2 and CDK4, as well as cyclins A, B1, 
D1 and E decreased in response to 80 µM magnolol after 24 h while in PC3 cells (Figure 
2.6) the expression of CDK2 as well as cyclins A and D1 decreased in response to 80 µM 
magnolol after 24 h. In DU145 cells, CDK2 expression significantly decreased by 
approximately 62% after exposure to 80 µM magnolol for 24 h, but were unchanged at 40 
µM for 24 h. CDK4 expression decreased by approximately 22% and 55% in DU145 
cells exposed to 40 and 80 µM magnolol for 24 h, respectively, with a statistically 
significant change at 80 µM. In PC3 cells a statistically significant decrease in CDK2 
expression, by 61%, was observed after 24 h exposure to 80 µM magnolol, but remained 
unchanged at 40 µM. No significant changes were observed in CDK4 expression. Cyclin 
A protein expression levels were decreased by 55% and 75%, cyclin B1 by 29% and 
66%, cyclin D1 by 15% and 65% and cyclin E by 42% and 64% in DU145 cells exposed 
to 40 and 80 µM magnolol for 24 h, respectively, with all changes statistically significant 
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Figure 2.5: Magnolol affects expression of cell cycle proteins in DU145 cells in vitro. 
Cells were treated with either DMSO (Ctrl), 40 or 80 µM magnolol in DMSO as 
indicated for 24 h. Actin was used as a loading control (the actin used in Figure 2.5A is 
the same as that used in Figure 2.7A as these samples were run concurrently). Each blot 
shown is representative of results obtained from at least three replications using separate 
samples. (*) indicates statistical significance at P ≤ 0.05.
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Figure 2.6: Magnolol affects expression of cell cycle proteins in PC3 cells in vitro. Cells 
were treated with either DMSO (Ctrl), 40 or 80 µM magnolol in DMSO as indicated for 
24 h. Actin was used as a loading control (the actins used in Figure 2.6A and 2.6B are the 
same as those used in Figure 2.8A and 2.8B, respectively, as these samples were run 
concurrently). Each blot shown is representative of results obtained from at least three 
replications using separate samples. (*) indicates statistical significance at P ≤ 0.05.
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except for the change to cyclin D1 at 40 µM. In PC3 cells, the only statistically 
significant changes observed were a reduction of cyclin A expression by 48% after 
exposure to 80 µM magnolol for 24 h and a reduction in cyclin D1 expression by 39% 
and 57% after exposure to 40 and 80 µM magnolol, respectively, for 24 h.
 To further determine why expression of these key cell cycle proteins were affected 
by magnolol exposure in DU145 (Figure 2.7) and PC3 cells (Figure 2.8), protein 
expression levels of cell cycle inhibitors, specifically p16INK4a, p21, p27, pRBp107 and 
pRBp130, were also measured. No statistically significant change was observed in 
expression of p16INK4a, p21 or p27 in DU145 cells exposed to 40 or 80 µM magnolol for 
24 h. Statistically significant changes in protein expression were only observed in 
pRBp107 in PC3 cells. Protein expression of pRBp107 decreased by 47% and 88% in 
DU145 cells exposed to 40 and 80 µM magnolol, respectively, for 24 h. In PC3 cells, 
expression of pRBp107 decreased by 54% and 47% after 24 h exposure to 40 and 80 µM, 
respectively. Protein expression of pRBp130 increased by 29% in DU145 cells exposed 
to 40 µM magnolol, and increased by 15% in cells exposed to 80 µM magnolol for 24 h. 
 As alterations in the expression of p21 and p27 can occur relatively early and then 
enact changes in the cell cycle at later time points (Lee et al. 2008a), expression of these 
two proteins was examined after 6 h exposure to 40 and 80 µM magnolol in DU145 
(Figure 2.9) and PC3 cells (Figure 2.10). Expression of p21 increased by 5% and 15% 
after exposure to 40 and 80 µM magnolol, respectively, in DU145 cells after 6 h. 
Expression on p21 also increased by 49% and 43% after exposure to 40 and 80 µM 
magnolol, respectively, in PC3 cells after 6 h. Protein expression of p27 remained
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Figure 2.7: Magnolol affects expression of cell cycle inhibitors in DU145 cells in vitro. 
Cells were treated with either DMSO (Ctrl), 40 or 80 µM magnolol in DMSO as 
indicated for 24 h. Actin was used as a loading control (the actin used in Figure 2.7A is 
the same as that used in Figure 2.5A as these samples were run concurrently). Each blot 
shown is representative of results obtained from at least three replications using separate 
samples. (*) indicates statistical significance at P ≤ 0.05.
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Figure 2.8: Magnolol affects expression of cell cycle inhibitors in PC3 cells in vitro. Cells 
were treated with either DMSO (Ctrl), 40 or 80 µM magnolol in DMSO as indicated for 
24 h. Actin was used as a loading control (the actins used in Figure 2.8A and 2.8B are the 
same as those used in Figure 2.6A and 2.6B, respectively, as these samples were run 
concurrently). Each blot shown is representative of results obtained from at least three 
replications using separate samples. (*) indicates statistical significance at P ≤ 0.05.
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Figure 2.9: Magnolol affects expression of p21 and p27 after 6 h in DU145 cells in vitro. 
Cells were treated with either DMSO (Ctrl), 40 or 80 µM magnolol in DMSO as 
indicated for 6 h. Actin was used as a loading control. Each blot shown is representative 
of results obtained from at least three replications using separate samples. (*) indicates 
statistical significance at P ≤ 0.05.
75
Figure 2.10: Magnolol affects expression of p21 and p27 after 6 h in PC3 cells in vitro. 
Cells were treated with either DMSO (Ctrl), 40 or 80 µM magnolol in DMSO as 
indicated for 6 h. Actin was used as a loading control. Each blot shown is representative 
of results obtained from at least three replications using separate samples. (*) indicates 
statistical significance at P ≤ 0.05.
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unchanged at 40 µM exposure to magnolol after 6 h in both DU145 and PC3 cells, but 
increased by 34% and 58% after exposure to 80 µM magnolol for 6 h in DU145 and PC3 
cells, respectively.
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2.4 Discussion
In this study, the effect of magnolol on the behavior of DU145 and PC3 human prostate 
cancer cells in vitro was examined. Specifically, magnolol was found to be cytotoxic to 
cells and to elicit alterations in the cell cycle, thereby preventing the cells from entering 
the G2/M-phase. Associated with these cell cycle alterations, protein expression of several 
key cell cycle proteins was affected. The concentrations of magnolol used in the present 
study were 40 and 80 µM for 24 h, similar to those concentrations used in previous 
studies on the effects of magnolol on various cancer cell lines in vitro (Chuang et al. 
2011; Hsu et al. 2007; Hwang and Park 2010; Lee et al. 2008a). The lower concentration 
used in this study, 40 µM, is equivalent to the highest tested concentration of magnolol 
measured in the blood plasma of rats injected with 10 mg/kg magnolol in a previous 
study (Tsai et al. 1996). This concentration can therefore be reasonably achieved in in 
vivo models. The in vitro cytotoxicity observations in the present study confirm previous 
in vitro cytotoxicity work using DU145 and PC3 cells exposed to magnolol by Lee et al. 
(2009) upon which the concentrations used in this study were based. This basis allowed 
this study to show, for the first time, that magnolol can cause alterations to the cell cycle 
in human prostate cancer cells and that expression of cell cycle proteins can be modulated 
by magnolol.
 One of the hallmarks of cancer is dysregulation of the cell cycle leading to 
unmitigated cell growth and division (Hanahan and Weinberg 2011). The present study is 
consistent with other literature showing that magnolol can cause alterations in the cell 
cycle in cancerous cells in vitro. Flow cytometric analysis showed that DU145 and PC3 
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cells underwent cell cycle changes in response to 40 and 80 µM magnolol exposure after 
24 h; both DU145 and PC3 cells showed an increased proportion of cells in the G0/G1-
phase of the cell cycle and a decreased proportion in the G2/M-phase. A G0/G1 arrest in 
response to magnolol exposure is observed in human colon and liver cancer cells (Lin et 
al. 2002) and in human glioblastoma cells (Chen et al. 2009). However, a G2/M-phase 
arrest of the cell cycle was observed in human urinary bladder cells (Lee et al. 2008a) 
and cell cycle arrest in the S-phase was found in human gastric cancer cells (Rasul et al. 
2012). Honokiol, a structural isomer of magnolol, has also previously been found to 
cause cell cycle arrest in the G0/G1-phase of human prostate cancer cells (Hahm and 
Singh 2007) and human breast cancer cells (Wolf et al. 2007). From this it appears that 
the cellular response to magnolol differs in cells from different organs or tissues of origin, 
with various cell types showing cell cycle arrest in different phases of the cell cycle. 
 Associated with changes to the cell cycle are changes in expression of key cell 
cycle proteins. Schwartz and Shah (2005) provide an overview of the cell cycle, 
describing the function of each cyclin and CDK protein: cyclin D1 acts with CDK2, 
CDK4 and CDK6 to progress the cell through the G1-phase, cyclin E acts in conjunction 
with CDK2 to transition the cell into the S-phase, cyclin A and CDK2 progress the cell 
through the S-phase and cyclin B1 is involved in mitosis. Alterations of the cell cycle 
resulting in a decreased number of cells entering the G2/M-phase would therefore 
necessitate interruption of the expression of cyclin D1, cyclin E, CDK2 or CDK4; all 4 of 
which show decreased expression in the presence of magnolol in DU145 cells and two of 
which (cyclin D1 and CDK2) show decreased expression in the presence of magnolol in 
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PC3 cells. This is consistent with other studies showing a G0/G1-phase arrest in human 
cancer cells. Chen et al. (2009) observed a decrease in cyclin D1 and cyclin A in human 
glioblastoma cells exposed to magnolol in vitro. Lin et al. (2002) also observed a 
decrease in cyclin A, cyclin E and CDK2 in human colon cancer cells exposed to 
magnolol in vitro. When PC3 cells were exposed to honokiol by Hahm and Singh (2007), 
decreased expression of cyclin D1, cyclin E, CDK2 and CDK4 was observed. The 
similarities between the two compounds, magnolol and honokiol, as well as the use of the 
same cell line suggests that similar results should be expected in the present study and 
this is what was observed. This study shows, for the first time, that magnolol affects the 
protein expression of cell cycle inhibitors at leading to alterations of the cell cycle at later 
time points.
 The expression of these cyclins and CDKs are controlled by several inhibitor 
proteins which may also have been affected by magnolol exposure. To this end, protein 
expression of several key cell cycle inhibitor proteins (including p16INK4a, p21, p27, 
pRBp107 and pRBp130) was determined by Western blot analysis. No significant 
changes were observed in the expression of p16INK4a, p21 or p27 after 24 h exposure to 
either 40 or 80 µM magnolol. This was unexpected as an increase in the expression of 
these proteins would lead to a decrease in many of the cyclins and CDKs: particularly, 
p16INK4a inhibits CDK4 which is responsible for the transition from G1 to S-phase; p21 
and p27 broadly inhibit CDKs and can prevent CDK-cyclin complexes from forming, 
thereby preventing progression through the cell cycle as well (Johnson and Walker 1999; 
Vermeulen et al. 2003). In their examination of the effects of honokiol on human prostate 
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cancer cells in vitro, Hahm and Singh (2007) found that expression of p21 increased in 
PC3 cells exposed to honokiol up to 8 h of exposure and subsequently decreased to basal 
levels thereafter, returning to levels comparable to the control by 24 h. As a result, protein 
expression of p21 and p27 was examined in DU145 and PC3 cells after 6 h exposure to 
magnolol, where both proteins trended toward increased expression with p27 showing a 
significant increase at 80 µM at the 6 h time point in both cell lines. Eto (2013) found that 
p27 expression was inversely related to carcinogenic risk in vivo in mouse models, 
concluding that a loss of p27 increased the chance of these mice developing cancer. 
Similarly to the present study, Lee et al. (2008a) observed an increase in p27 expression 
and no change in p21 expression in human urinary bladder cancer cells in vitro after 
exposure to magnolol. Colon cancer and glioblastoma cells exposed to magnolol 
increased p21 expression with no observed change in p27 expression (Lin et al. 2002; 
Rasul et al. 2012).
 Finally, pRBp107 and pRBp130 protein expression levels were examined by 
Western blot analysis to determine if altered expression of these proteins was involved in 
the cellular response to magnolol. Expression of pRBp107 protein level was significantly 
reduced at both 40 and 80 µM magnolol in both DU145 and PC3 cells while pRBp130 
protein expression level exhibited a significant increase at 40 µM in DU145 cells. Only a 
nonsignificant trend toward increased protein expression of pRBp130 protein was 
observed at the higher, 80 µM, concentration. The pRB proteins are also involved in the 
regulation of the cell cycle, with pRBp107 and pRBp130 typically mediating the 
inhibitory effects of p16INK4a (Leng et al. 2002). In this sense, cells lacking pRBp107 or 
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pRBp130 did not undergo the cell cycle arrest typical of increased p16INK4a expression 
(Bruce et al. 2000). As no significant change was observed in p16INK4a expression in the 
present study, the decreased pRBp107 protein expression would likely not play a role in 
the observed changes to the cell cycle through this pathway. The E2F family of proteins 
are associated with progression from G1 to S-phase of the cell cycle and pRBp130 is 
known to bind these E2F proteins and thereby stop cell cycle progression (Mayol and 
Graña 1997). As increased expression of pRBp130 protein was observed in the present 
study, this could be one possible explanation for the observed cell cycle alterations. It has 
also been suggested that differential regulation of pRBp130 and pRBp107, consisting of 
increased pRBp130 expression and decreased pRBp107 expression, is associated with 
exit from the cell cycle in serum dependent cells subsequently deprived of serum; the 
opposite was found to be true in cells transitioning from G1 to S-phase where pRBp130 
expression was lowered and pRBp107 expression increased (Mayol and Graña 1997; 
Smith et al. 1996).
 In conclusion, this study has demonstrated that magnolol is able to induce 
alterations in the cell cycle resulting in a decreased number of cells entering the G2/M-
phase of the cell cycle in the DU145 and PC3 androgen insensitive human prostate cancer 
cell lines in vitro. These cell cycle alterations are associated with changes in the 
expression of key cell cycle regulatory proteins, most notably cyclins A, B1, D1 and E, 
CDK 2 and CDK4, p27 and pRBp130. In completing this study the anti-cancer properties 
of magnolol in vitro are further elucidated and contribute to the body of evidence 
suggesting that magnolol has potential as a novel anti-prostate cancer agent. This study 
82
highlights the role of magnolol in altering the cell cycle of human prostate cancer cells in 
vitro through modulation of cell cycle protein expression as well as alterations to the 
protein expression of cell cycle inhibitors. Further research is required to determine if the 
effects observed in the present study also occur in androgen sensitive prostate cancer cell 
lines, such as LNCaPs, and to determine if the in vitro effects observed in the present 
study are replicable in an in vivo model.
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CHAPTER THREE
Magnolol Affects Cellular Proliferation, Polyamine Biosynthesis and Catabolism-
Linked Protein Expression and Associated Cellular Signaling Pathways in Human 
Prostate Cancer Cells In Vitro2
3.1 Introduction
Prostate cancer is the most commonly diagnosed form of cancer in men in Canada and 
the United States, representing roughly 10% of cancer related deaths in men in both 
countries (ACS 2011; CCS 2013). As a result there is an increased interest in the research 
of natural products, many of which have traditionally been used in herbal medicines, and 
their bioactive effects and potential chemoprotective and chemopreventative capacities 
(Bemis et al. 2006; Ikarashi et al. 2001; Zhang et al. 2005).
 Magnolol, a lignan found in the roots and bark of the magnolia tree Magnolia 
officinalis, has previously been shown to affect important cellular processes such as the 
cell cycle and apoptosis in a variety of human cancer cell types both in vitro and in vivo 
(Chuang et al. 2011; Hsu et al. 2007; Hwang and Park 2010; Kim et al. 2007; Lee et al. 
2009; Lee et al. 2008a; Lin et al. 2001, 2002; Rasul et al. 2012). Those studies performed 
in vivo suggest that magnolol remains active when administered at a sufficient oral 
dosage. Animal models have been used to determine the bioavailability of magnolol 
using two delivery methods: oral administration and intravenous injection. It was found 
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2 The results of this study have been previously published in the Journal of Functional 
Foods in Health and Disease (McKeown and Hurta 2015). This chapter is an adaptation 
and reformatting of that publication.
that an injected dose of 2-10 mg/kg could achieve a maximum blood plasma 
concentration of 10 µg/ml or 40 µM magnolol while oral administration of 20 mg/kg 
could achieve a maximum blood plasma concentration of 0.1 µg/ml or 0.4 µM magnolol 
(Ho and Hong 2012; Lin et al. 2011; Tsai et al. 1996). Magnolol has also been shown to 
be non-toxic and to have no drug related side effects at any dose including the highest 
tested doses in several studies (Ho and Hong 2012; Li et al. 2007; Liu et al. 2007). These 
previously observed effects warrant further investigation into the mechanisms by which 
the cell responds to the anti-cancer effects of magnolol.
 Polyamines (putrescine, spermidine and spermine) are essential to various cellular 
processes, particularly cellular growth, and the levels of polyamines are carefully 
controlled within a narrow range (Perez-Leal and Merali 2012). These compounds can 
bind to RNA, DNA and proteins to change their functions or to increase their expression; 
one of the most common ways in which polyamines affect cells is in their binding to 
mRNA and stimulating protein synthesis by causing structural changes (Igarashi and 
Kashiwagi 2009). The biosynthesis of polyamines is controlled by ornithine 
decarboxylase (ODC), a rate limiting factor in the conversion of ornithine to putrescine, 
S-adenosylmethionine decarboxylase (SAMDC) is then responsible for further 
biosynthesis from putrescine to spermidine and from spermidine to spermine. Polyamine 
catabolism is controlled by two further proteins, polyamine oxidase (PAO) and 
spermidine/spermine N1-acetyltransferase (SSAT), both of which are capable of 
converting spermine to spermidine and spermidine to putrescine. Elevated polyamine 
levels have been associated with prostate cancer and altered expression of the rate 
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limiting enzymes involved in both polyamine biosynthesis and catabolism are often 
observed during the development of cancer (Nowotarski et al. 2013). In particular, ODC 
expression is generally increased in human cancers and therapies targeting these 
polyamine biosynthetic/catabolic enzymes have been used in both chemotherapy and in 
chemoprevention (Nowotarski et al. 2013). 
 In the present study, the in vitro effects of magnolol on the expression of proteins 
involved in the biosynthesis and catabolism of polyamines in PC3 human prostate cancer 
cells were examined. This is novel research as the effects of magnolol on this polyamine 
pathway have not yet been investigated. Furthermore this investigation seeks to 
determine the degree to which polyamine related proteins are modulated in response to 
magnolol exposure and to characterize the cellular signaling mechanisms involved in the 
effect of magnolol on cellular proliferation.
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3.2 Materials and Methods
All antibodies used in this study were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). These include: goat polyclonal anti-ODC, anti-AZ, anti-R1, anti-R2, 
anti-p-JNK, anti-JNK-1, anti-p-PI3Kp85, anti-Akt, anti-Histone H2B and anti-p-IκBα; 
mouse polyclonal anti-actin, anti-PAO, anti-SAMDC, anti-PI3Kp85 and anti-IκBα; and 
rabbit polyclonal anti-SSAT, anti-AZI, anti-p-ERK, anti-ERK-1, anti-ERK-2, anti-p-p38, 
anti-p38, anti-JNK-2, anti-PI3Kp110, anti-p-Akt, anti-NFκBp65, anti-c-jun and anti-c-
fos. Magnolol was purchased from LKT Laboratories, Inc. (St. Paul, MN). All other 
chemicals and materials were purchased from Sigma-Aldrich Canada (Oakville, ON) 
unless otherwise indicated.
3.2.1 Cell Culture and Treatment with Magnolol
Human PC3 prostate adenocarcinoma cells (ATCC, Manasses, VA) were cultured on 100 
mm plastic tissue-culture dishes (Falcon, Mississauga, ON) in RPMI (Gibco, Burlington, 
ON) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic 
(Invitrogen Canada, Burlington, ON), and were incubated at 37 0C in 5% CO2. At 70% 
confluence, cells were exposed to 80 µM concentrations of magnolol, dissolved in 
dimethyl sulfoxide (DMSO), for 6 h [concentration of DMSO in both magnolol-treated 
and control cells was 0.2% (v/v)]. Control cells received only DMSO. After treatment, 
cells were removed using trypsin diluted in phosphate buffered saline (PBS) and re-
suspended in RPMI with 10% FBS and centrifuged for 5 min at 500x G. The medium 
was then removed by aspiration. The remaining cell pellet was re-suspended and washed 
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in cold PBS. Cells were again centrifuged for 5 min at 500x G. After centrifugation, the 
PBS was removed by aspiration and the pellet was then stored at -80 0C until further 
analysis.
3.2.2 Cellular Proliferation Curve
PC3 human prostate adenocarcinoma cells were subcultured at 25000 cells/plate on 100 
mm plastic tissue culture dishes in RPMI supplemented with 10% FBS and 1% 
antibiotic-antimycotic. Following 24 h of incubation, cells were counted using a 
haemocytometer to determine cell number at the 0 h time point. Cells were then treated 
with either 80 µM magnolol in DMSO or DMSO alone (control). Cells were again 
counted at 6, 24, 48 and 72 h time points. Triplicate plates were counted for each 
treatment (control or 80 µM magnolol) at each time point.
3.2.3 Nuclear and Cytosolic Protein Fraction Isolation
Nuclear and cytosolic protein isolation was performed using a nuclear extraction kit 
(Cayman Chemical, Ann Arbor, MI) as per manufacturer’s instruction. Briefly, cells were 
treated and pelleted as above then cell pellets were suspended in 250 µL of hypotonic 
buffer (10% 10x hypotonic buffer, 2% phosphatase inhibitors, 1% protease inhibitors, 
87% distilled water) and incubated on ice for 15 min. After 15 min, 50 µL of 10% 
Nonident P-40 assay reagent was added to each sample and mixed by pipetting. Samples 
were centrifuged at 14000x G for 30 sec at 4 0C. The supernatant was then removed and 
stored at -80 0C as this represents the cytosolic fraction. The remaining cell pellet was 
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resuspended in 50 µL of extraction buffer (50% 2x nuclear extraction buffer, 2% 
phosphatase inhibitors, 1% protease inhibitors, 37% distilled water) and vortexed for 15 
sec, then shaken for 15 min at 0 0C. Samples were vortexed, for 30 sec, and shaken a 
second time for 15 min at 0 0C. Finally, samples were centrifuged at 14000x G for 10 min 
at 4 0C and the supernatant, representing the nuclear fraction, was removed and stored at 
-80 0C until further immunoblot analysis.
3.2.4 Immunoblot Analysis
Cell pellets (for those sample not undergoing nuclear isolation) were re-suspended in 100 
µl of 10 mM Tris-HCl buffer (pH 7.4) containing 0.5 mM PMSF, and briefly sonicated. 
Cell lysates were then centrifuged at 9300x G for 20 min at 4 0C. The supernatant was 
removed from the pellet as this represents a whole cell lysate sample. Nuclear, cytosolic 
and whole lysate samples were evaluated for protein content. Equal amounts of protein 
from these extracts were mixed in a 3:1 ratio with standard Laemmli buffer consisting of 
50 mM Tris-HCl (pH 6.8), 10% SDS, 0.1% bromophenol blue, 10% glycerol and 100 
mM β-mercaptoethanol and boiled for 3 min. Electrophoresis through 10% SDS-PAGE 
gels was used to resolve proteins which were then transferred onto nitrocellulose 
membranes (Bio-Rad, Mississauga, ON) by electro-blotting. Membranes were then 
incubated in the presence of a 1% BSA (w/v) TBS-Tween (0.05% v/v) solution overnight 
at 4 0C. Primary antibodies diluted to 1:200 (v/v) were then applied to membranes and 
incubated for 1 h at room temperature. After incubation, the membranes were washed 
three times with TBS-Tween (0.05% v/v) for a total of 30 min then incubated with 
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alkaline phosphatase (AP)-conjugated secondary antibodies (1:1000) for 1.25 h at room 
temperature. After incubation the membranes were again washed three times with TBS-
Tween (0.05%) for a total of 30 min and rinsed quickly with distilled water, then exposed 
to SigmaFast BCIP-NBT tablets (Sigma-Aldrich, Oakville, ON) dissolved in distilled 
water to visualize protein expression levels. Western blots were then photographed using 
Infinity Capture Software (Lumenera Corp., Ottawa, ON) and densitometry was 
performed with ImageJ Software (National Institute of Health, Bethesda, MD).
3.2.5 Statistical Analysis
Statistical analysis was conducted using GraphPad Prism 4.03 for Windows (GraphPad 
Software, Inc. San Diago, CA). Cell counts in cellular proliferation curve were compared 
to corresponding cell count for control cells at the appropriate time point using a simple t-
test and results were considered statistically significant at P ≤ 0.1. Results of immunoblot 
analysis were compared using a simple t-test and results were considered statistically 
significant at P ≤ 0.1.
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3.3 Results
3.3.1 Magnolol Affects Cellular Proliferation
It has previously been shown that magnolol is cytotoxic to PC3 human prostate cancer 
cells in vitro, as discussed in Chapter Two of this thesis (Lee et al. 2009; McKeown et al. 
2014). To confirm that this cytotoxicity is accompanied by reduced cellular proliferation 
a cellular proliferation curve experiment was conducted (Figure 3.1). Time course 
experiments show that cellular proliferation is retarded in PC3 cells exposed to 80 µM 
magnolol. At 6 h exposure to magnolol there was no significant difference in cellular 
proliferation between magnolol exposed and control cells, but by 24 h a statistically 
significant difference in cell numbers was observed whereby control cell count increased 
to 231% of 0 h cell count and magnolol exposed cell count only increased to 151% of 0 h 
cell count. Cellular proliferation in magnolol exposed cells essentially stopped at 48 h 
where cell counts were 154% of 0 h counts, only a 2% increase from 24 h counts. By 72 
h magnolol exposed cell counts were lower than the 0 h count while control cells counts 
were at 714% of 0 h counts.
3.3.2 Magnolol Affects Proliferation-Linked Protein Expression
Having established that magnolol exposure results in decreased cellular proliferation, 
expression of proteins involved in two important proliferation-linked activities were 
examined. In PC3 cells exposed to 80 µM magnolol for 6 h the protein expression of 
ornithine decarboxylase (ODC), antizyme inhibitor (AZI), spermidine/spermine N1-
acetyltransferase (SSAT) and polyamine oxidase (PAO) decreased significantly after
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Figure 3.1: Magnolol affects cellular proliferation of PC3 human prostate cancer cells in 
vitro. Both a line graph (A) and a bar graph (B) of this data set is presented for 
comparative purposes. Cells were treated with either DMSO (Ctrl) or 80 µM magnolol in 
DMSO for 6, 24, 48 or 72 h. The number of cells present under these conditions were 
determined in three separate experiments for each time point. Statistical significance 
between control and magnolol treated cells was determined at each time point. (*) 
indicates statistical significance at P ≤ 0.1 and (**) indicates statistical significance at P ≤ 
0.05.
92
A
B
exposure to magnolol while protein expression of S-adenosylmethionine decarboxylase 
(SAMDC) increased (Figure 3.2). Antizyme (AZ) protein expression remained 
unchanged (Figure 3.2). While ODC protein expression decreased to 68% of control and 
AZI protein expression decreased to 73% of control, protein expression of SAMDC 
increased to 154%. Of those proteins directly involved in polyamine catabolism, SSAT 
protein expression decreased to 66% of control and PAO protein expression decreased to 
43% of control.
 To further determine the effect of magnolol on cellular proliferation in PC3 cells 
the two subunits of ribonucleotide reductase (R1 and R2) were assayed (Figure 3.3). As 
ribonucleotide reductase is necessary for the synthesis of deoxyribonucleoside 
triphosphates, the building material for DNA, changes in protein expression of the R1 or 
R2 subunits would represent an important pathway by which cellular proliferation may be 
affected (Guarino et al. 2014; Norlund and Reichard 2006). Ribonucleotide reductase is 
tightly linked to DNA synthesis and changes to either subunit suggest similar changes to 
DNA synthesis. While R1 protein expression was not significantly affected by magnolol 
exposure the protein expression of R2 decreased to 62% of control.
3.3.3 Magnolol Affects Cellular Signaling Pathway Protein Expression
Following the changes observed in expression of polyamine biosynthesis and catabolism-
linked proteins several cellular signaling pathways were assayed to determine which, if 
any, of these pathways may be involved in the cellular response to magnolol exposure. 
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Figure 3.2: Magnolol affects expression of polyamine biosynthesis/catabolism-linked 
proteins in PC3 cells in vitro. Cells were treated with either DMSO (Ctrl) or 80 µM 
magnolol in DMSO for 6 h. Actin was used as a loading control (the actin used in Figure 
3.2A is the same as those used in Figures 3.3B, 3.4B and 3.5B; the actin used in Figure 
3.2B is the same as those used in Figures 3.3A and 3.5C as these samples were run 
concurrently). Each blot shown is representative of results obtained from at least three 
replications from three separate experiments. A, B and C: Representative Western blots of 
proteins involved in polyamine biosynthesis and catabolism. D: Graphical representation 
of protein expression. (*) indicates statistical significance at P ≤ 0.1 and (**) indicates 
statistical significance at P ≤ 0.05.
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Figure 3.3: Magnolol affects expression of R2 subunit of ribonucleotide reductase in PC3 
cells in vitro. Cells were treated with either DMSO (Ctrl) or 80 µM magnolol in DMSO 
for 6 h. Actin was used as a loading control (the actin used in Figure 3.3A is the same as 
those used in Figures 3.2B and 3.5C; the actin used in 3.3B is the same as those used in 
Figures 3.2A, 3.4B and 3.5B as these samples were run concurrently). Each blot shown is 
representative of results obtained from at least three replications from three separate 
experiments. A and B: Representative Western blots of the R1 and R2 proteins, 
respectively. C: Graphical representation of protein expression. (*) indicates statistical 
significance at P ≤ 0.1.
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By investigating these cellular signaling pathways and their regulators the signaling 
mechanism(s) through which magnolol acts can be further elucidated.
 Of the MAPK pathways (Figure 3.4) proteins the expression of the following 
were significantly altered: p-p38 decreased to 75%, c-Jun N-terminal kinase (JNK)-2 
decreased to 81%, JNK-1 decreased to 41% and p-JNK-1 increased to 116% (Figure 3.4). 
Of the PI3K pathway proteins (Figure 3.5) the expression of the following were 
significantly altered: PI3Kp85 decreased to 26%, p-PI3Kp85 decreased to 74% and p-Akt 
decreased to 63% (Figure 3.5). The expression of the following proteins of the NFκB 
pathway (Figure 3.6) were significantly altered from control: NFκBp65 nuclear fraction 
decreased to 60%, NFκBp65 cytosolic fraction decreased to 88%, p-IκBα decreased to 
76% and nuclear factor of kappa-B inhibitor (IκBα) decreased to 84%. Finally, of the 
transcription factors involved in the activator protein-1 (AP-1) pathway (Figure 3.6) 
assayed, the expression of c-jun significantly increased to 207% while no statistically 
significant change was observed in expression of the c-fos protein.
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Figure 3.4: Magnolol affects expression of MAPK pathway proteins in PC3 cells in vitro. 
Cells were treated with either DMSO (Ctrl) or 80 µM magnolol in DMSO for 6 h. Actin 
was used as a loading control (the actin used in Figure 3.4A is the same as that used in 
Figure 3.5A; the actin used in 3.4B is the same as those used in Figures 3.2A, 3.3B and 
3.5B as these samples were run concurrently). Each blot shown is representative of 
results obtained from at least three replications from three separate experiments. A and B: 
Representative Western blots of proteins involved in MAPK pathways. C: Graphical 
representation of protein expression. (**) indicates statistical significance at P ≤ 0.05.
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Figure 3.5: Magnolol affects expression of PI3K pathway proteins in PC3 cells in vitro. 
Cells were treated with either DMSO (Ctrl) or 80 µM magnolol in DMSO for 6 h. Actin 
was used as a loading control (the actin used in Figure 3.5A is the same as that used in 
Figure 3.4A; the actin used in 3.5B is the same as those used in Figures 3.2A, 3.3B and 
3.4B as these samples were run concurrently). Each blot shown is representative of 
results obtained from at least three replications from three separate experiments. A: 
Representative Western blots of Akt and p-Akt proteins. B: Representative Western blots 
of PI3K proteins. C: Representative Western blot of phosphorylated PI3Kp85 protein. D: 
Graphical representation of protein expression. (**) indicates statistical significance at P 
≤ 0.05.
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Figure 3.6: Magnolol affects expression of NFκB and AP-1 pathway proteins in PC3 cells 
in vitro. Cells were treated with either DMSO (Ctrl) or 80 µM magnolol in DMSO for 6 
h. Actin was used as a loading control. Each blot shown is representative of results 
obtained from at least three replications from three separate experiments. A: 
Representative Western blot of histone H2B protein indicating nuclear protein 
enrichment. B: Representative Western blots of cytosolic fraction proteins of NFκB and 
AP-1 pathways. C: Representative Western blots of nuclear fraction proteins of NFκB 
and AP-1 pathways. D: Graphical representation of protein expression. (*) indicates 
statistical significance at P ≤ 0.1 and (**) indicates statistical significance at P ≤ 0.05.
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3.4 Discussion
In this study the effect of magnolol on the behavior of PC3 human prostate cancer cells in 
vitro was examined. As discussed in Chapter Two of this thesis, magnolol has been found 
to cause alterations in expression of cell cycle proteins in DU145 and PC3 human 
prostate cancer cells (McKeown et al 2014). In the present study, magnolol was found to 
affect cellular proliferation through alterations to proteins involved in polyamine 
biosynthesis and catabolism. Cellular proliferation of PC3 cells exposed to magnolol was 
reduced after 24 h exposure and cell number remained virtually unchanged when cells 
were counted 48 h after exposure. Decreased protein expression of ODC in response to 
magnolol suggests that production of putrescine from ornithine is being limited. This is 
supported by reduced protein expression of AZI and unchanged protein expression of AZ. 
AZ acts as a non-competitive inhibitor of ODC, with AZ and ODC forming a dimer and 
increasing ODC degradation (Pegg 2006). By increasing protein expression of AZ in an 
in vivo mouse model of upper aerodigestive tract cancers, carcinogenesis was reduced 
and polyamine levels decreased (Feith et al. 2013). A reduction in AZI protein expression 
coupled with no significant change in AZ protein expression should similarly cause 
available AZ to be increased. Decreased ODC protein expression has also been associated 
with induction of apoptosis in MCF-7 breast cancer cells in vitro (Arisan et al. 2012). 
Magnolol has previously been shown by Lee et al. (2009) to induce apoptosis in PC3 
human prostate cancer cells. The decreased protein expression of ODC observed in the 
present study combined with the finding of Lee et al. (2009) could indicate a similar 
connection between decreased ODC expression and apoptosis.
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 SAMDC functions in production of spermidine from putrescine and spermine 
from spermidine. The increase in SAMDC protein expression is opposite to that of ODC 
suggesting that SAMDC may be compensating for the loss of ODC in driving polyamine 
production forward. In in vivo mouse models, an increase in SSAT protein expression 
was accompanied by increasing ODC protein expression, compensating for the increased 
polyamine catabolism by increasing biosynthesis (Kee et al. 2004; Tucker et al. 2005). 
This suggests that the decreases in SSAT and PAO in the present study may be due to a 
similar compensatory mechanism whereby decreased polyamine biosynthesis through 
reduced ODC protein expression is compensated with reduced SSAT and PAO protein 
expression resulting in reduced polyamine catabolism. Inhibition of PAO has also 
previously been linked to induction of apoptosis in certain leukemia cell lines in vitro 
(Wallace and Fraser 2004).
 In assaying the protein expression of the R1 and R2 subunits of ribonucleotide 
reductase, only the protein expression of the R2 subunit decreased. As ribonucleotide 
reductase functions in converting ribonucleosides to deoxyribonucleosides, this enzyme 
is of key importance to cellular proliferation. R1 protein is constitutively expressed 
throughout the cell cycle, but R2 protein expression is most closely associated with the S-
phase of the cell cycle (Guarino et al. 2014; Norlund and Reichard 2006). The change in 
the availability of the R2 subunit is due both to changes in protein expression as well as 
changes in protein degradation (Guarino et al. 2014). The R2 subunit is also recognized 
as the rate-limiting factor in conversion of ribonucleosides to deoxyribonucleosides, 
thereby acting as an important regulator of DNA synthesis with inhibition of this R2 
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subunit slowing down DNA synthesis (Guarino et al. 2014). As a result of its intimate ties 
to DNA synthesis, ribonucleotide reductase has been the target of chemotherapies in 
various types of cancer (Guarino et al. 2014). As magnolol has previously been shown to 
cause alterations in the cell cycle of PC3 human prostate cancer cells in vitro, the 
reduction of R2 protein expression in the current study further supports reduced 
proliferation and reduced ability for PC3 cells to proceed through the cell cycle in the 
presence of magnolol (McKeown et al. 2014). 
 Finally, several cellular signaling pathways were assayed to determine which, if 
any, are affected in the cellular response to magnolol exposure. In the MAPK pathways, 
magnolol has previously been shown to decrease protein expression of p38 and increase 
extracellular signal-regulated kinase p-(ERK)-1/2 protein expression with no significant 
change to protein expression of ERK-1/2 nor p-p38 in SKOV3 human ovarian cancer 
cells in vitro (Chuang et al. 2011). In COLO-205 human colon cancer cells in vitro 
magnolol exposure was associated with an increase in p-ERK-1/2 protein expression but 
protein expression of ERK-1/2 was not affected (Hsu et al. 2007). In human urinary 
bladder cancer 5637 cells in vitro exposed to 60 µM magnolol for 3, 6 and 12 h an 
increase in protein expression of p-ERK-1/2, p-p38 and p-JNK-1/2 with no apparent 
change in the non-phosphorylated forms occurred (Lee et al. 2008a). In U373 human 
malignant glioblastoma cells in vitro exposed to magnolol, increased protein expression 
of p-ERK-1/2 and p-p38 were observed after exposure to 100 µM magnolol for 60 min 
with no change to JNK-1/2, ERK-1/2, p38 or p-JNK-1/2 (Chen and Lee 2013). In VSMC 
human aortic smooth muscle cells in vitro no effect on ERK-1/2 or p-ERK-1/2 was 
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observed in response to magnolol (Kim et al. 2007). In the present study, the alterations 
to the MAPK pathways are relatively minor, with significant changes only occurring in p-
p38, JNK-1/2 and p-JNK-1. The changes to MAPK protein expression are variable 
throughout these previous studies with no observed change to ERK-1/2 observed in any 
of the referenced studies and increases in protein expression of p-ERK-1/2 occurring in 
all studies aside from the present investigation and that of Kim et al. (2007). Inhibition of 
ERK-1/2 and p-ERK-1/2 has previously been associated with decreased expression of 
ODC in human leukemia L1210 cells in vitro, and increased ERK-1/2 and p-ERK-1/2 has 
associated with increased ODC. As no change in expression of these proteins was 
observed in the present study it is unlikely that they are involved in the decrease of ODC 
expression in response to magnolol observed (Flamigni et al. 1999). Protein expression of 
p-p38 is especially variable with increases in expression observed by Chen and Lee 
(2013) and Lee et al. (2008a), no change observed by Chuang et al. (2011) and a decrease 
in expression observed in the present study. The highly variable effect of magnolol on 
proteins of the MAPK pathways are likely due to these proteins being differently 
expressed across various cell lines.
 Unlike the variable nature of the effect of magnolol on the MAPK pathways, the 
effects of magnolol on the expression of those proteins involved in the PI3K/Akt pathway 
appear to be conserved across cell lines. The PI3K/Akt signaling pathway has previously 
been found to be involved in apoptosis-related signaling in various cancer cell lines in 
vitro in response to magnolol exposure (Chuang et al. 2011; Lee et al. 2009; Rasul et al. 
2012). These studies observed decreased protein expression of p-PI3K and p-Akt with no 
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change in protein expression of Akt. The results of the present study support those 
observations of a previous study by Lee et al. involving PC3 human prostate cancer cells 
in that alterations to cellular viability were associated with these changes to the PI3K 
pathway, but show an additional change in PI3Kp85 which was not observed previously 
(2009). This change may be related to the higher concentration of magnolol, 80 µM as 
opposed to 60 µM, used in the present study. While the PI3K pathway is typically 
associated with cell survival it also plays an important role in activating proliferation by 
controlling cyclin D and p27 activity (Vivanco and Sawyers 2002). The PI3K pathway 
can also control cell growth through mTOR, with decreased PI3K expression resulting in 
decreased cellular growth though this pathway (Vivanco and Sawyers 2002). The 
decreased activation of the PI3K/Akt pathway observed in the present study may affect 
both cellular growth and proliferation though these mechanisms. 
 The protein expression of NFκBp65 decreased in the cytoplasm and within the 
nucleus in the present study. This suggests that there is reduced expression of this protein 
and that translocation of NFκBp65 into the nucleus is reduced in response to magnolol 
exposure. NFκB is an inhibitor of apoptosis as well as being involved in the transcription, 
and activation, of cyclin D (Karin et al. 2002). Lastly, the increased protein expression of 
c-jun observed in the present study is contrary to the anti-proliferative effect of magnolol 
on PC3 human prostate cancer cells. As increased c-jun transcription is generally 
associated with increased cellular proliferation, it is possible that protein expression of c-
jun is increased in a compensatory manner. While protein expression of c-fos was not 
significantly altered in response to magnolol exposure in the present study the increased 
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expression of c-jun may act in concert with stable expression of c-fos to activate the AP-1 
pathway. While reduced expression of c-jun and c-fos is associated with decreased 
cellular proliferation, increased expression of these two proteins involved in the AP-1 
pathway can also be an indication of apoptotic conditions although it is unknown if there 
is a functional role played by the AP-1 pathway or if it is merely an associated indicator 
(Shaulian and Karin 2002).
 In conclusion, the present study has shown for the first time that magnolol does 
affect expression of proteins involved in cellular proliferation-linked activities. These 
alterations to the expression of proteins involved in cellular proliferation occurred in PC3 
human prostate cancer cells in vitro. These effects were modulated through alterations in 
multiple cellular signaling pathways. This study is also novel in representing the most 
thorough investigation of the effects of magnolol on the cellular signaling pathways in 
human prostate cancer cells. Although the effect of magnolol on the MAPK signaling 
pathways are highly variable between various cancer cell types, the PI3K pathway is 
consistently altered and as such is a likely pathway by which magnolol affects cellular 
proliferation. Changes in the NFκB pathway similarly suggest that PC3 response to 
magnolol exposure is to reduce cellular proliferation. Further research is required to 
determine the effects of magnolol on cellular proliferation in an in vivo model, and to 
determine if magnolol affects cellular proliferation through alternative pathways such as 
disruptions to growth factor signaling.
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CHAPTER FOUR
Magnolol Affects Expression of IGF-I and Associated Binding Proteins in Human 
Prostate Cancer Cells In Vitro3
4.1 Introduction
In Canada and the United States, prostate cancer is the most commonly diagnosed form 
of cancer among men and the second most common cancer among men worldwide (ACS 
2011). This study continued previous investigation on the effects of magnolol, a 
compound found in the roots and bark of the magnolia tree Magnolia officinalis, by 
determining further pathways by which magnolol exposure may alter cellular 
proliferation. Specifically, this study investigated the effect of magnolol on insulin-like 
growth factor-I (IGF-I), the insulin-like growth factor-I receptor (IGF-IR) and the 
associated insulin-like growth factor binding proteins (IGFBPs) in PC3 and LNCaP 
human prostate cancer cells in vitro.
 Insulin-like growth factors (IGFs) are involved in cellular growth, differentiation 
and apoptosis avoidance (Furlanetto et al. 1994; Yu and Rohan 2000). The cellular 
response to IGF is initiated through IGF binding to IGF-receptors (IGF-Rs). IGF action is 
regulated by IGFBPs, whether by increasing IGF half-life or by promoting/inhibiting IGF 
binding to IGF-Rs (Weinzimer et al. 2001). The IGFBPs function by having a greater 
binding affinity for IGF than do the IGF-Rs, thereby blocking the normal signaling 
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3 The results of this study have been previously published in the journal Anticancer 
Research (McKeown and Hurta 2014). This chapter is an adaptation and reformatting of 
that publication.
interaction and allowing IGFBPs to functionally remove IGFs from the system in this 
way (Yu and Rohan 2000). IGFBPs also exhibit a range of IGF-independent activities: 
increased IGFBP-3 can result in reduced protein synthesis or induce apoptosis, while 
IGFBP-2 and IGFBP-5 can induce mitosis (Firth and Baxter 2002). Dramatic changes in 
IGFBP expression has also been associated with cancer, particularly in that IGFBP-2 and 
IGFBP-5 over-expression correlates with the change from androgen sensitivity to 
androgen independence in prostate cancer cells (DeGraff et al. 2007, 2009; Miyake et al. 
2000). The present study examines the effect of magnolol on IGF-I and associated protein 
expression in two prostate cancer cell lines in vitro.
4.2 Materials and Methods
All antibodies used in this study were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). The antibodies used included: mouse polyclonal anti-actin, anti-IGF-
IR, anti-IGFBP-2 and anti-IGFBP-3; goat polyclonal anti-IGF-I; and rabbit polyclonal 
anti-p-IGF-IR, anti-IGFBP-4 and anti-IGFBP-5. Magnolol was purchased from LKT 
Laboratories, Inc. (St. Paul, MN). All other chemicals and materials were purchased from 
Sigma-Aldrich Canada (Oakville, ON) unless otherwise indicated.
4.2.1 Cell Culture and Treatment with Magnolol
Human PC3 prostate adenocarcinoma cells (ATCC, Manasses, VA) and human LNCaP 
prostate adenocarcinoma cells (ATCC) were cultured on 100 mm plastic tissue-culture 
dishes (Falcon, Mississauga, ON) in RPMI (Gibco, Burlington, ON) supplemented with 
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10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic (Gibco), and were 
incubated at 37 0C in 5% CO2. After incubation, cells were exposed to 80 µM magnolol, 
dissolved in dimethyl sulfoxide (DMSO), for 6 h. Control cells received only DMSO. 
Magnolol (80 µM) was previously determined to be an effective concentration via 
cytotoxicity studies as discussed in Chapter Two of this thesis (McKeown et al. 2014). 
After treatment, cells were removed using trypsin diluted in phosphate buffered saline 
(PBS) and re-suspended in RPMI with 10% FBS and centrifuged for 5 min at 500x G. 
The medium was then aspirated off leaving only a cell pellet and the cells were 
resuspended and washed in cold PBS. Cells were again centrifuged for 5 min at 500Xg. 
After centrifugation, the PBS was aspirated off and the cell pellet was stored at -80 0C 
until further analysis.
4.2.2 Immunoblot Analysis
Cell pellets were resuspended in 100 µl of 10 mM Tris-HCl buffer (pH 7.4) containing 
0.5 mM PMSF, and briefly sonicated. Cell lysates were then centrifuged at 9300x G for 
20 min at 4 0C. The supernatant was removed from the pellet and evaluated for protein 
content. Equal amounts of protein from this extract were mixed in a 3:1 ratio with 
standard Laemmli buffer consisting of 50 mM Tris-HCl (pH 6.8), 10% SDS, 0.1% 
bromophenol blue, 10% glycerol and 100 mM β-mercaptoethanol and boiled for 3 min. 
Electrophoresis through 10% SDS-PAGE gels was used to resolve proteins, which were 
then transferred onto nitrocellulose membranes (Bio-Rad, Mississauga, ON) by 
electroblotting. Membranes were then incubated in the presence of a 1% BSA (w/v) TBS-
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Tween (0.05% v/v) solution overnight at 4 0C. Primary antibodies diluted to 1:200 (v/v) 
were then applied to membranes and incubated for 1 h at room temperature. After 
incubation, the membranes were washed 3 times with TBS-Tween (0.05% v/v) for a total 
of 30 min, then incubated with alkaline phosphatase (AP)-conjugated secondary 
antibodies (1:1000) for 1.25 h at room temperature. After incubation, the membranes 
were again washed 3 times with TBS-Tween (0.05%) for a total of 30 min and rinsed 
quickly with distilled water, then exposed to SigmaFast BCIP-NBT tablets (Sigma) 
dissolved in distilled water to visualize protein expression levels. Western blots were then 
photographed using Infinity Capture Software (Lumenera Corp., Ottawa, ON) and 
densitometry was performed with ImageJ Software (National Institute of Health, 
Bethesda, MD).
4.2.3 Statistical Analysis
Statistical analysis was conducted using Graphpad Prism 4.03 for Windows (Graphpad 
Software, Inc. San Diego, CA). Results of immunoblot analysis were compared a simple 
t-test and results were considered statistically significant at P ≤ 0.1.
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4.3 Results
4.3.1 Magnolol Affects IGF-I and IGFBP Expression
Protein expression of IGF-I, IGF-IR and IGFBPs were altered in PC3 (Figure 4.1) and in 
LNCaP (Figure 4.2) human prostate cancer cells after 6 h exposure to 80 µM magnolol. 
This magnolol exposure resulted in a reduction to 56% IGF-I in PC3 cells. Similarly, in 
LNCaP cells, magnolol exposure resulted in a significant IGF-I reduction to 70% of 
control. To determine if changes in IGF-I expression in response to magnolol were 
affected by changes in the IGFBPs, protein expression of IGFBP-2, IGFBP-3, IGFBP-4 
and IGFBP-5 were also examined. Protein expression of IGFBP-2 was not significantly 
affected in either PC3 or LNCaP cells. IGFBP-3 protein expression increased 
significantly in both cell lines: to 132% in LNCaP cells and to 142% in PC3 cells. 
IGFBP-4 protein expression was not significantly affected by magnolol exposure in PC3 
cells; however, expression was increased to 160% without attaining significance. In 
LNCaP cells IGFBP-4 protein expression was increased to 171%. The final IGFBP 
assayed, IGFBP-5, showed a significant decrease in protein expression in both LNCaP 
and PC3 cells in response to magnolol treatment at 79% and 68%, respectively. Finally, 
to determine if magnolol exposure would affect IGF signaling, the protein expression of 
IGF-IR and its phosphorylated form were examined. Neither IGF-IR nor p-IGF-IR were 
significantly affected by magnolol exposure in LNCaP cells; however, IGF-IR protein 
expression increased to 130% without attaining statistical significance. In PC3 cells the 
protein expression of IGF-IR increased to 132%, while the protein expression of p-IGF-
IR decreased to 65%. 
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Figure 4.1: Magnolol affects expression of IGF-I and associated proteins in PC3 human 
prostate cancer cells in vitro. Cells were treated with either DMSO (Ctrl) or 80 µM 
magnolol in DMSO for 6 h. Actin was used as a loading control. Each blot shown in 
Figure 4.1A is representative of results obtained in triplicate using separate samples. 
These triplicate results are represented as changes in protein expression in the graphs in 
Figure 4.1B. (*) indicates statistical significance at P≤0.1 and (**) indicates statistical 
significance at P≤0.05.
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Figure 4.2: Magnolol affects expression of IGF-I and associated proteins in LNCaP 
human prostate cancer cells in vitro. Cells were treated with either DMSO (Ctrl) or 80 
µM magnolol in DMSO for 6 h. Actin was used as a loading control. Each blot shown in 
Figure 4.2A is representative of results obtained in triplicate using separate samples. 
These triplicate results are represented as changes in protein expression in the graphs in 
Figure 4.2B. (*) indicates statistical significance at P≤0.1 and (**) indicates statistical 
significance at P≤0.05.
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4.4 Discussion
The IGFBPs are a complicated group of proteins with a variety of functions both 
dependent and independent of IGFs. In this study, the effects of magnolol, a compound 
found in the roots and bark of the magnolia tree Magnolia officinalis, have been 
examined on the expression of IGF-I, IGF-IR and several IGFBPs in LNCaP and PC3 
cells in vitro. Magnolol exposure resulted in significantly reduced protein expression of 
IGF-I in both cell lines after 6 h at a concentration of 80 µM. Changes were also observed 
in IGF-IR and the IGFBPs at this concentration and time point.
 IGF-I functions to increase cellular uptake of amino acids and promote 
carbohydrate metabolism through stimulation of glycogen and protein synthesis (Yu and 
Rohan 2000). Stimulation of the cell cycle can also result from elevated IGF-I levels as 
IGF-I can increase the synthesis and stimulation of cyclin D1 (Furlanetto et al. 1994; You 
et al. 2002), and IGF-I expression has been associated with increased protein expression 
of cyclin D1 and CDK4 in MCF-7 cells (Mawson et al. 2005). The decrease in IGF-I 
observed in the present study corresponds to a decrease in cyclin D1 expression in PC3 
and DU145 cells exposed to magnolol in vitro as observed in Chapter Two of this thesis 
(McKeown et al. 2014). As alterations in the cell cycle were also observed in the 
aforementioned study (McKeown et al. 2014), it is possible that decreased IGF-I protein 
expression observed in the present study may be involved in the altered cell cycle 
response to magnolol previously described. 
 IGF-I function is mediated by IGF-IR. IGF-R is activated via phosphorylation and 
subsequently activates the phosphatidylinositol 3-kinase (PI3K) and mitogen activated 
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protein kinase (MAPK) pathways (Shukla and Gupta 2009). As IGF-IR protein 
expression increased by similar amounts in both LNCaP and PC3 cells, achieving 
statistical significance only in PC3 cells, this would suggest an increase in IGF-I 
signaling and therefore increased cellular proliferation. Protein expression of the 
phosphorylated form, p-IGF-IR, was significantly decreased in PC3 cells, while 
expression was unchanged in LNCaP cells. This suggests that, while the expression of 
IGF-IR is increasing, perhaps in a compensatory manner in response to decreased IGF-I 
expression, p-IGF-IR is either decreasing in protein expression or unchanged and, 
therefore, IGF-I signaling is not increasing. This relationship of decreased IGF-I and 
either decreased or unchanged p-IGF-IR could be one further explanation of changes to 
the PI3K and MAPK signaling pathways in response to magnolol previously observed 
(Chen and Lee 2013; Chuang et al. 2011; Hsu et al. 2007; Kim et al. 2007; Lee et al. 
2008a).
 IGFBP-2 is directly involved in growth stimulation and has been suggested to be 
implicated with progression from androgen sensitivity to androgen independence 
(DeGraff et al. 2007, 2009; Moore et al. 2003). In the present study the protein 
expression of IGFBP-2 was not significantly altered from control values in either LNCaP 
or PC3 cells. This was unexpected as decreases in IGF-I have previously been associated 
with decreased IGFBP-2 protein expression as IGFBP-2 functions to stabilize IGF-I and 
thereby increase its half-life (Clemmons 1997).
 IGFBP-3 protein expression increased in both LNCaP and PC3 cells after 6 h 
exposure to magnolol in vitro. IGFBP-3 is generally associated with the induction of anti-
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metastatic functions and acts as a tumor suppressor in mouse models (Mehta et al. 2011). 
This increase in IGFBP-3 expression could be involved in other magnolol-mediated 
changes to metastasis observed previously (Chuang et al. 2011; Hwang and Park 2010; 
Kim et al. 2007).
 In the present study the most pronounced increase to protein expression in both 
LNCaP and PC3 cells occurred in IGFBP-4 although this increase was only statistically 
significant in LNCaP cells. IGFBP-4 acts by inhibiting IGF-I action and, therefore, 
inhibiting cellular growth and proliferation, with the main role of IGFBP-4 in normal 
cells being the protection of cells from overstimulation by IGF (Clemmons 1997). The 
increased expression of IGFBP-4 observed in the present study provides an additional 
and novel pathway by which alterations to cellular growth and proliferation previously 
described may occur (McKeown et al. 2014). When increased IGFBP-4 protein 
expression is considered in conjunction with decreased IGF-I protein expression the net 
result is a lowered availability of IGF-I to the cell. This IGF-I is involved in activating 
cellular signaling pathways, particularly the MAPK and PI3K pathways (Krishna and 
Narang 2008; Pollak 2008). As previously observed, magnolol exposure results in 
decreased expression of PI3K proteins (McKeown and Hurta 2015). The PI3K pathway 
is, in part, responsible for control of proteins involved in progression through the cell 
cycle (Fresno Vara et al. 2004; Vivanco and Sawyers 2002). The expression of these cell 
cycle proteins have previously been shown to decrease in response to magnolol exposure 
(McKeown et al. 2014). The present study therefore contributes important and novel 
information to our understanding of how magnolol affects human prostate cancer cell in 
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vitro by highlighting some of the earliest alterations occurring in the cellular signaling 
mechanism. In vivo studies have shown that either an increase or decrease in IGFBP-4 
expression can delay tumor formation (Durai et al. 2006).
 IGFBP-5 expression was significantly lower in both LNCaP and PC3 cells 
exposed to magnolol. Decreases in IGFBP-5 have previously been associated with 
decreases in anti-apoptotic activity and may be involved in the apoptotic response to 
magnolol previously described (Cobb et al. 2004; Lin et al. 2001). Decreases in IGFBP-5 
expression have also been associated with inhibition of IGF-I activities involving DNA 
synthesis and cellular metabolism (Clemmons et al. 1997).
 The progression from androgen sensitivity to androgen independence may be 
inhibited by decreased IGFBP-5 expression (Miyake et al. 2000). By decreasing 
IGFBP-5 expression there is a resultant loss of IGF-I bioavailability, which in turn results 
in decreased progression through the cell cycle (Furlanetto et al. 1994). This is supported 
by in vivo models where IGFBP-5 was found to have no effect on apoptosis but 
functioned in regulating the cell cycle in prostate cancer cells in a rat model (Thomas et 
al. 1998).
 Magnolol exposure to decreases IGF-I expression through two mechanisms: 
protein expression of IGF-I is directly decreased, as well as indirectly affected by the 
IGFBPs. By decreasing the availability of IGF-I in these two ways the anti-proliferative 
and anti-apoptotic effects of magnolol may be controlled by this system of IGF-I and 
IGFBPs interacting both individually, as well as additively or synergistically. Further 
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research studies examining the effect of magnolol on other aspects of cancer cell 
progression and control, such as metastasis and apoptosis, are warranted.
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CHAPTER FIVE
General Discussion and Future Directions
5.1 General Discussion
The results obtained through the experiments described in this thesis indicate that 
magnolol affects cellular growth and proliferation linked processes within human prostate 
cancer cells in vitro. As described in Chapters Two, Three and Four, magnolol causes 
alterations in the expression of key proteins involved in the cell cycle, polyamine 
proliferation and IGF regulation.
 In Chapter Two, magnolol was shown to be cytotoxic to human prostate cancer 
cells in vitro, confirming the findings of Lee et al. (2009) and establishing the effective 
concentration to be used throughout this thesis. It has also been previously established 
that magnolol is non-toxic to untransformed cells at these concentrations in vitro, and is 
non-toxic with no associated side-effects in mouse and rat models in vivo (Ho and Hong 
2012; Lee et al. 2009; Li et al. 2007; Liu et al. 2007). These toxicity experiments did not, 
however, investigate the effects of magnolol on reproductive health. While no negative 
reproductive side effects have been associated with magnolol, magnolol is a 
phytoestrogen and other phytoestrogens have been know to cause impaired fertility and 
other reproductive disorders and justifies further research in this area be undertaken 
(Mitchell et al. 2001). Furthermore, magnolol was shown to alter cell cycle progression 
by altering cellular expression of the cyclins, CDKs and their inhibitors. In Chapter 
Three, magnolol was shown to affect the expression of proteins involved in polyamine 
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biosynthesis and catabolism as well as the expression of proteins involved in various 
cellular signaling pathways. Finally, in Chapter Four, magnolol was shown to affect the 
expression of IGF-I and the IGFBPs which help to regulate it.
 While each of these chapters focuses on one aspect of cellular growth or 
proliferation in human prostate cancer cells in vitro, it is the cellular signaling pathways 
described in Chapter Two which unite these chapters into a single, cohesive project. The 
proteins of the cell cycle are the driving force of proliferation, and it is this set of proteins 
which the cellular signaling pathways are ultimately affecting. The polyamines 
themselves are intricately linked to the cell cycle, with polyamine concentrations being 
highest in cells during the G1/S-phase transition (Oredsson et al. 1984; Wallace et al. 
2003). While the exact nature of this connection between the cell cycle and increased 
polyamine concentration is unknown, it is thought that polyamines are necessary for 
DNA replication to occur and possibly playing a role in cyclin degradation (Oredsson et 
al. 1984; Wallace et al. 2003). The PI3K/Akt signaling pathway was the most 
consistently altered signaling cascade in response to magnolol in the experiments 
conducted for this thesis. Downstream of PI3K signaling, both ODC and key cell cycle 
inhibitors such as p21 and p27 are controlled (Flamigni et al. 1997; Fresno Vara et al. 
2004; Rajeeve et al. 2013; Vivanco and Sawyers 2002). It has been suggested that it is 
this relationship by which PI3K activation can so effectively cause cancerous activity and 
proliferation: by increasing cellular polyamine concentration through increased 
expression of ODC and by promoting cell cycle progression through decreased 
expression of cell cycle inhibitors (Rajeeve et al. 2013). As described in this thesis, cells 
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exposed to magnolol show decreased cell cycle activity, increased expression of p27 and 
decreased expression of ODC which is consistent with an inhibition of the relationship 
described above. This thesis is unique in linking alterations to IGF-I and its associated 
binding proteins, the proteins of polyamine biosynthesis and catabolism and the proteins 
involved in the cell cycle together through the cellular signaling pathways in the response 
of human prostate cancer cells to magnolol exposure in vitro. All of these processes play 
an important role in human prostate cancer and are affected by magnolol exposure as is 
shown in this thesis for the first time.
 Cell cycle proteins are also among the downstream targets of the MAPK 
pathways, the NFκB pathway and the AP-1 pathway. These cellular signaling pathways 
are further interconnected, with Akt activating the NFκB pathway through inhibition of 
IκBα, and the NFκB  and JNK pathways being major activators of c-jun which in turn 
activates the AP-1 pathway (Fujioka et al. 2004; Vivanco and Sawyers 2002; Wagner and 
Nebreda 2009). The alterations in protein expression in each of these pathways observed 
in response to magnolol exposure in this thesis could have led to cell cycle alterations. 
Upstream of these signaling pathways is IGF-1. While the IGFBPs regulate IGF-I, IGF-I 
signaling leads to the downstream activation of the PI3K, MAPK, NFκB and AP-1 
signaling pathways which ultimately result in changes of expression in proteins involved 
in the cell cycle as described above (Pollak 2004).
 When the data described within this thesis are considered as a whole, they 
describe magnolol as a compound capable of affecting a wide range of cellular growth 
and proliferation and linked activities. Magnolol has been shown to cause similar effects 
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in a variety of cell lines, lending credence to the results found here, as well as 
strengthening the support for magnolol having an anti-cancer effect (Chen et al. 2009; 
Hsu et al. 2007; Lee et al. 2008a; Lin et al. 2002).
 These studies were exclusively based on in vitro assays. While in vitro studies are 
effective in the early stages of investigating a compound to determine its usefulness and 
potential benefits, particularly in justifying later in vivo studies by showing a compound 
to be effective in altering protein expression or cellular behavior, it would be preferable 
to provide some information acquired through in vivo experimentation. The limitation 
with in vitro studies lies in that the cells are directly exposed to the compound of interest, 
in this case magnolol, without first passing through the digestive tract of the animal nor 
requiring that the compound be transported to them via the circulatory system. This 
means that in vitro studies can be conducted at much higher concentrations for much 
longer exposures than are feasible or even possible in vivo. To counteract this, a 
concentration was chosen which should be attainable in vivo as discussed above. 
Similarly, due to the broad nature of experiments conducted within this thesis, in vivo 
experiments would prove much more time consuming and would not be feasibly 
accomplished within a reasonable timeframe.
 Each of the pathways described in this thesis affect cellular growth or 
proliferation through independent mechanisms discussed throughout this thesis, but it is 
important to note that these systems are interconnected and do not occur in isolation from 
one another. The processes described within this thesis are happening in conjunction with 
one another and so it would be inadvisable to consider any one of these mechanisms the 
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sole reason for the effect magnolol produces in preventing prostate cancer cell growth in 
vitro. Likewise, it is important to consider other potential factors not discussed within this 
thesis, which may form the basis for future studies regarding the effect of magnolol in 
human prostate cancer cells in vitro. This thesis shows that magnolol can affect growth 
and proliferation linked activities in human prostate cancer cells in vitro through each of 
these mechanisms, highlighting the importance of magnolol as a potential 
chemoprotective and chemopreventative compound in human prostate cancer.
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5.2 Future Directions
This project focused on the effects of magnolol on cellular growth and proliferation in 
human prostate cancer cells in vitro, while studies by others investigating the effects of 
magnolol on apoptosis and metastasis have previously been performed (Hwang et al. 
2010; Lee et al. 2009). Certain aspects of these processes remain to be investigated. The 
specific mechanism by which IGF-I signaling occurs could be elucidated by measuring 
protein expression of known signaling targets in the presence of magnolol, IGF-I and 
both magnolol and IGF-I to determine if magnolol can counteract the effect of excess 
IGF-I and to ensure that the expression of these specific targets of IGF-I are being 
affected. The cellular polyamine concentrations could also be measured by HPLC, both 
in the presence and absence of magnolol, to determine to what extent magnolol-induced 
changes in the biosynthetic and catabolic proteins affect these polyamine concentrations. 
While it has been shown by Hwang et al. (2010) that magnolol can affect expression of 
MMPs and inhibit cellular invasion, other proteins involved in cellular adhesion could be 
examined in more detail (as is currently being done in our lab).
 Beyond this, other hallmarks of cancer as described by Hanahan and Weinberg 
(2011) remain to be investigated, such as the effects of magnolol on angiogenesis. More 
broadly, the mechanisms by which magnolol interacts with cells to induce the observed 
effects could be determined, not only to gain insight on how magnolol behaves at the 
molecular level and induces such cellular responses as those observed, but also to help 
understand how similar compounds work and to more effectively develop compounds 
with stronger effects.
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 It also remains to expand this research from in vitro assays to studies involving in 
vivo models of human prostate cancer such as TRAMP mice. This would serve to 
determine if the concentrations used in this thesis are attainable in vivo in practice, as 
well as determining if magnolol shows similar inhibition of cancer cell growth and 
proliferation in vivo. Further toxicity studies, including the effects of long term magnolol 
exposure on reproductive health, need also be undertaken. Similar in vivo studies have 
been performed on nude mice implanted with human colon cancer cells, showing that 
these cells will increase p21 expression and undergo apoptosis (Lin et al. 2002). The 
previous in vivo studies, combined with the in vitro studies described in this thesis and 
elsewhere, suggest that magnolol will perform similarly in preventing cellular growth and 
proliferation in vivo and warrant further investigation.
 Two compounds closely related to magnolol, honokiol and obovatol, have also 
been subject to scientific interest for their potential anti-cancer activity. Both honokiol 
and obovatol have been previously shown to inhibit cell cycle progression in human 
prostate cancer cells (Hahm et al. 2008; Hahm and Singh 2007; Lee et al. 2008b). At the 
time of writing, no papers are known to have been published investigating the effect of 
either honokiol or obovatol on IGF and the IGFBPs, nor on polyamine proliferation. It 
would also be of interest to study magnolol, honokiol and obovatol in combination as 
these compounds exist together in nature. It is possible that cellular responses to these 
compounds observed in isolation are not representative of the full potential of the 
compounds produced by Magnolia officinalis as these compounds may work 
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synergistically in nature. These studies would aid in the investigation of this family of 
compounds and help to characterize their effect on cellular growth and proliferation.
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5.3 Summation
In summary, magnolol can affect the behavior of human prostate cancer cells in vitro. The 
studies described within this thesis show that magnolol has anti-cancer activity as well as 
chemoprotective and chemopreventative effects. These effects include alterations of the 
cell cycle, as well as changes in expression of proteins involved in the cell cycle, 
polyamine proliferation and regulation of IGF-I. As these effects are clearly 
demonstrated, and similar effects can be found in the literature, further studies into the 
effects of magnolol on prostate cancer cells, particularly in vivo, are warranted.
 This work shows, for the first time, that magnolol affects expression of proteins 
involved in polyamine biosynthesis and catabolism. It is also uniquely shown that 
magnolol affects expression of cell cycle proteins and IGF-I in human prostate cancer 
cells in vitro. These results are significant because they highlight magnolol as a promising 
anti-cancer compound and justify further research in in vivo models of prostate cancer for 
the further development of magnolol as a chemopreventative and chemoprotective drug.
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APPENDIX A
American Cranberry (Vaccinium macrocarpon) Extract Affects Expression of 
Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Proteins in 
Human Prostate Cancer Cells In Vitro
A.1 Abstract
American cranberry (Vaccinium macrocarpon) extract has previously been shown to 
affect cell cycle, apoptosis and proliferative ability in prostate cancer cells in vitro. The 
insulin-like growth factors (IGFs) and their modulators, specifically the insulin-like 
growth factor binding proteins (IGFBPs) may play roles in these events. The present 
study tested IGF-I and IGFBPs expression in DU145 and PC3 prostate cancer cells after 
exposure to 50 µg/ml or 100 µg/ml of whole cranberry extract (WCE) for 24 h in vitro. 
Western blot analysis was used to show that protein expression levels of IGF-I, IGFBP-2 
and IGFBP-5 decrease whereas IGFBP-4 protein expression levels increase and IGFBP-3 
protein expression levels were not significantly altered after exposure to WCE. Alteration 
in expression of IGF-I and the IGFBPs may be physiologically important as these 
proteins have been linked to changes in the cell cycle, apoptosis and matrix 
metalloproteinase activity. The changes in IGF-I and IGFBP expression observed in this 
study also indicate decreased IGF-I activity which suggests an inhibition of cellular 
growth, induction of apoptosis and anti-metastatic activity in vitro. These WCE mediated 
changes in IGF-I and IGFBP expression are novel and further indicate the potential 
chemoprotective and chemopreventative actions of cranberry in vitro.
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A.2 Introduction
Cancer is the second leading cause of death worldwide, with prostate cancer being the 
second most commonly diagnosed form in men (ACS 2011). As a result, many patients 
seek to manage this disease through life style and dietary changes (Bemis et al. 2006). 
 The American Cranberry (Vaccinium macrocarpon) is a small plant typical of peat 
bogs in cool temperate regions of eastern North America (Stewart and Nilsen 1995). The 
fruit of V. macrocarpon has been shown to contain biologically active phytochemicals 
such as anthocyanins, flavonols and proanthocyanidins (Déziel et al. 2012; MacLean et 
al. 2011). These compounds have previously been shown to affect cell cycle, apoptosis 
and proliferative ability in vitro in prostate cancer cells (Déziel et al. 2010, 2012; 
MacLean et al. 2007, 2011). 
 One promising mechanistic avenue for the loss of anti-apoptotic and proliferative 
ability due to exposure to whole cranberry extract previously discussed by Déziel et al. 
(2010, 2012) and MacLean et al. (2007, 2011) are the insulin-like growth factors (IGFs) 
and their modulators, specifically the insulin-like growth factor binding proteins 
(IGFBPs). The IGFs are responsible for increased cellular growth by increasing 
metabolic activity and increased mitogenic activity, specifically through anti-apoptotic 
activity and stimulating the expression of cyclin D1 to progress the cell cycle (Furlanetto 
et al. 1994; Yu and Rohan 2000). These IGFs bind to IGF-receptors (IGF-Rs) on the cell 
membrane thereby initiating a cascade of reactions to induce the previously mentioned 
effects. The IGFBPs act by regulating IGF action, specifically through increasing IGF 
half-life and by either promoting or inhibiting IGF binding to IGF-Rs (Weinzimer et al. 
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2001). The IGFBPs function by having a greater IGF binding affinity than do the IGF-Rs, 
thereby blocking IGF and IGF-R interaction and protecting IGFs from proteolysis (Yu 
and Rohan 2000). The IGFBPs can then functionally remove IGF from the system by 
remaining bound to it, or increase IGF bioavailability by protecting IGFs from 
proteolysis and thus retain elevated levels of IGF for the cells (Yu and Rohan 2000). The 
IGFBPs also exhibit a range of IGF-independent activities, particularly in reducing 
protein synthesis and inducing apoptosis for increased IGFBP-3 expression and inducing 
mitosis for increased IGFBP-2 and IGFBP-5 expression (Firth and Baxter 2002). 
Furthermore, IGFBP activity in cancer cells has been the subject of much interest and 
atypical expression of these IGFBPs has been associated with dramatic changes in 
cellular behavior such as IGFBP-2 and IGFBP-5 over-expression correlating with the 
change from androgen sensitivity to androgen independence in prostate cancer cells 
(DeGraff et al. 2007, 2009; Miyake et al. 2000). The present study examines the effect of 
whole cranberry extract (WCE) on IGF-I and IGFBP protein expression in two prostate 
cancer cell lines in vitro. 
 Our laboratory has previously examined the effects of WCE on various cellular 
processes and behaviors in prostate cancer cells in vitro including cell cycle (Déziel et al. 
2012), apoptosis (MacLean et al. 2011) and mitogenic activity (Déziel et al. 2010; 
MacLean et al. 2007). This study was designed to identify and then characterize a cellular 
process which could unify the previously observed and elucidated effects of cranberry on 
prostate cancer cells in vitro while additionally describing the novel effects of WCE on 
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the IGF-IGFBP signaling axis; as such the main focus of this study is specifically the 
effects of WCE on IGF and the IGFBPs.
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A.3 Materials and Methods
All antibodies used in this study were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). The antibodies used included: mouse polyclonal anti-actin, anti-
IGFBP-2, and anti-IGFBP-3; rabbit polyclonal anti-IGFBP-4 and anti-IGFBP-5; and goat 
polyclonal anti-IGF-I. Solvents for HPLC analysis of WCE were purchased from Fisher 
Scientific (Pittsburgh, PA) and reagent-grade acetone, methanol and ethyl acetate were 
purchased from Pharmco Products Inc. (Brookfield, CT). Diaion® HP-20 was purchased 
from Supelco, Inc. (Bellefonte, PA). Cyanidin and quercetin glycoside standards were 
from Chromadex (Irvine, CA) and procyanidin A2 from Indofine Chemical 
(Hillsborough, NJ). All other chemicals and materials were purchased from Sigma-
Aldrich Canada (Oakville, ON) unless otherwise indicated.
A.3.1 Preparation of Cranberry Extract
Cranberry fruit (Vaccinium macrocarpon) was harvested in November 2008 at the State 
Bog in Wareham, Massachusetts. The fruit was flash-frozen in liquid nitrogen and stored 
at -20 0C. until use.  Whole cranberry extract (WCE) was prepared as described 
previously (Déziel et al. 2012). Briefly, 1 kg of fruit was extracted several times with 300 
ml aliquots of 40/40/19/1 methanol/acetone/water/formic acid at room temperature each 
time pulsing with a Waring blender for 5 min, and filtering after 30 min, and collecting 
the filtrate. This was repeated with the pulp until most of the color was gone.  The 
combined filtrates were concentrated in vacuo and then freeze-dried. Free sugars were 
removed by applying the sample to a Diaion HP-20 column and washing several times 
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with distilled water. Elution with methanol followed by acetone, evaporation and freeze-
drying of combined extracts produced 10.5 g. of concentrated whole cranberry extract 
(WCE). 
The WCE was analyzed with a Waters HPLC chromatography system equipped 
with two pumps, an ultraviolet-visible photodiode array detector and Millennium 
software, using a Waters (Milford, MA) Symmetry C18 reversed phase column (4.6 X 
250 mm) and gradient elution program employing solvent A (4% aqueous acetic acid) 
and solvent B (4% acetic acid in methanol) at a flow rate of 0.8 ml/min as previously 
described (Déziel et al. 2012). The program consisted of: gradient elution from 99% 
solvent A over 0-30 min, a gradient to 70% solvent A at 70 min. and gradient to 100% 
solvent B at 90 min.  Anthocyannin glycosides are detected at 520 nm, flavonol 
glycosides at 355 nm and proanthocyanidins at 280 nm. Content of proanthocyanidins 
was determined gravimetrically, by fractionation of the extract on Sephadex LH-20 to 
isolate the proanthocyanidins as previously described (MacLean et al. 2011). 
Proanthocyanidins were characterized by MALDI-TOF MS analysis to determine size 
and distribution of epicatechin oligomers as previously described (MacLean et al. 2011; 
Neto et al. 2006).
A.3.2 Cell Culture and Treatment with Whole Cranberry Extract
Human DU145 prostate adenocarcinoma cells (ATCC, Manasses, VA) and human PC3 
prostate adenocarcinoma cells (ATCC) were cultured on 100 mm plastic tissue-culture 
dishes (Falcon, Mississauga, ON) in α-MEM (Gibco, Burlington, ON) or RPMI (Gibco) 
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respectively, supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-
antimycotic (Gibco), and were incubated at 37 0C in 5% CO2. At 70% confluence the 
media was replaced with serum free α-MEM or RPMI, for DU145 cells and PC3 cells, 
respectively, supplemented with 5 µg/ml of transferrin and 2.5 µg/ml of insulin and 
incubated for 24 h at 37 0C in 5% CO2. After incubation, cells were exposed to either 50 
µg/ml or 100 µg/ml concentrations of WCE, dissolved in dimethyl sulfoxide (DMSO), for 
24 h. Control cells received only DMSO. After treatment, cells were removed by trypsin 
diluted in phosphate buffered saline (PBS) and re-suspended in either α-MEM or RPMI, 
for DU145 cells and PC3 cells, respectively, with 10% FBS and centrifuged for 5 min at 
500x G. The media was then aspirated off leaving only a cell pellet, and the cells re-
suspended and washed in cold PBS. Cells were again centrifuged for 5 min at 500x G. 
After centrifugation the PBS was aspirated off and the cell pellet was stored at -80 0C. 
until further analysis.
A.3.3 Immunoblot Analysis
Cell pellets were resuspended in 100 µl of 10 mM Tris-HCl buffer (pH 7.4) containing 
0.5 mM PMSF, and briefly sonicated. Cell lysates were then centrifuged at 9300x G for 
20 min at 4 0C. The supernatant was removed from the pellet and evaluated for protein 
content. Equal amounts of protein from this extract were mixed in a 3:1 ratio with 
standard Laemmli buffer consisting of 50 mM Tris-HCl (pH 6.8), 10% SDS, 0.1% 
bromophenol blue, 10% glycerol and 100 mM β-mercaptoethanol and boiled for 3 min. 
Electrophoresis through 10% SDS-PAGE gels was used to resolve proteins which were 
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then transferred onto nitrocellulose membranes (Bio-Rad, Mississauga, ON) by 
electroblotting. Membranes were then incubated in the presence of a 1% BSA (w/v) TBS-
Tween (0.05% v/v) solution overnight at 4 0C. Primary antibodies diluted to 1:200 (v/v) 
were then applied to membranes and incubated for 1 h at room temperature. After 
incubation, the membranes were washed 3 times with TBS-Tween (0.05% v/v) for a total 
of 30 min then incubated with alkaline phosphatase (AP)-conjugated secondary 
antibodies (1:1000) for 1.25 h at room temperature. After incubation the membranes were 
again washed 3 times with TBS-Tween (0.05%) for a total of 30 min and rinsed quickly 
with distilled water, then exposed to SigmaFast BCIP-NBT tablets dissolved in distilled 
water to visualize protein expression levels. Western blots were then photographed using 
Infinity Capture Software (Lumenera Corp., Ottawa, ON) and densitometry was 
performed with ImageJ Software (National Institute of Health, Bethesda, MD).
A.3.4 Statistical Analysis
Statistical analysis was conducted using Graphpad Prism 4.03 for Windows (Graphpad 
Software, Inc. San Diego, CA). Results of immunoblot analysis were compared using a 
one way ANOVA with a Tukey’s Posthoc test and results were considered statistically 
significant at P ≤ 0.05.
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A.4 Results
A.4.1 Analysis of Whole Cranberry Extract
The WCE used in this study was analyzed concurrently with those used in previous 
studies, as such characterization of the WCE has been described previously (Déziel et al. 
2012; MacLean et al. 2011; Neto et al. 2006). The HPLC profile of this sample has also 
been previously reported (Déziel et al. 2012). Briefly, the major anthocyanin constituents 
identified in the WCE are cyanidin-3-galactoside, cyanidin-3-arabinoside, peonidin-3-
galactoside and peonidin-3-arabinoside. The WCE contained 10.3% anthocyanin by 
weight. The flavonol glycosides identified were quercetin-3-O-galactoside (major 
glycoside present), myricetin-3-galactoside, myricetin-3-arabinoside, quercetin-3-
xyloside, quercetin-3-arabinoside and quercetin-3-rhamnoside. The total flavonol 
glycoside content of the WCE was 9.9%. Peaks consistent with proanthocyanidins and p-
coumaric acid derivatives are also present. The total proanthocyanidin (PAC) content of 
the extract was 41% by weight. Proanthocyanidins were verified by characteristic peak 
elution patterns at 279.1 nm (which is the absorbance maximum for epicatechin-based 
proanthocyanidins). MALDI-TOF MS analysis found the PAC fraction contained 
proanthocyanidin oligomers ranging in size from two to twelve epicatechin units, 
primarily dimers (including procyanidin A2), trimers and tetramers with at least one A-
type linkage between units, as previously reported (MacLean et al. 2011).
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A.4.2 Effects of Whole Cranberry Extract on Expression of IGF-I and IGFBPs
As shown in Figure A.1, IGF-I expression was significantly reduced in PC3 and in 
DU145 human prostate cancer cells after 24 h of exposure to 100 µg/ml WCE. This WCE 
exposure resulted in a reduction to 50% of control IGF-I at 100 µg/ml in PC3 cells, with a 
reduction to 67% of control observed at 50 µg/ml in PC3 cells. Similarly, in DU145 cells, 
WCE exposure resulted in a significant IGF-I reduction to 33% and 22% of control at 50 
and 100 µg/ml respectively. To determine if changes in IGF-I expression in response to 
WCE were affected by changes in the IGFBPs, protein expression of IGFBP-2, IGFBP-3, 
IGFBP-4 and IGFBP-5 were also examined. Of the IGFBPs examined, significant 
changes to protein expression were observed in IGFBP-2, IGFBP-4 and IGFBP-5. In 
DU145 cells, the expression of IGFBP-2 was significantly reduced to 75% and 47% of 
control after 24 h of exposure to 50 and 100 µg/ml WCE, as shown in Figure A.2. This 
suppression was also observed to a lesser extent in PC3 cells, with no significant change 
at 50 µg/ml and a reduction to 77% of control at 100 µg/ml WCE (Figure A.3). IGFBP-3 
expression was not significantly altered at any exposure concentration after 24 h, 
however, a trend towards decreased expression in DU145 cells (Figure A.2) and 
increased expression in PC3 cells was evident (Figure A.3). IGFBP-4 expression did not 
change significantly in DU145 cells (Figure A.2), but a significant increase to 140% of 
control was observed at 50 µg/ml after 24 h in PC3 cells, while no significant change 
observed in response to treatment with 100 µg/ml WCE  after 24 h exposure as illustrated 
in Figure A.3. As shown in Figure A.2 and Figure A.3, respectively, expression of 
IGFBP-5 decreased significantly in both  DU145 cells and PC3 cells after 24 h exposure 
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to 100 µg/ml WCE to 73% and 66% of control respectively. PC3 cells also exhibited a 
significant decrease to 72% of control after exposure to 50 µg/ml WCE for 24 h (Figure 
A.3).
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Figure A.1: The effect of WCE on expression of IGF-I in PC3 and DU145 cells. Cells 
were treated with either DMSO (Ctrl), 50 or 100 µg/ml WCE in DMSO for 24 h. 
Representative IGF-I expression levels are shown with actin used as a loading control. 
Experiments were performed with at least three replications using separate samples. (*) 
indicates statistical significance at P ≤ 0.05.
156
Figure A.2: The effect of WCE on expression of IGFBPs in DU145 cells. DU145 cells 
were treated with either DMSO (Ctrl), 50 or 100 µg/ml WCE in DMSO for 24 h. 
Representative expression levels of IGFBP-2, -3, -4 and -5 are shown with actin used as a 
loading control. Experiments were performed with at least three replications using 
separate samples. (*) indicates statistical significance at P ≤ 0.05.
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Figure A.3: The effect of WCE on expression of IGFBPs in PC3 cells. PC3 cells were 
treated with either DMSO (Ctrl), 50 or 100 µg/ml WCE in DMSO for 24 h. 
Representative expression levels of IGFBP-2, -3, -4 and -5 are shown with actin used as a 
loading control. Experiments were performed with at least three replications using 
separate samples. (*) indicates statistical significance at P ≤ 0.05.
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A.5 Discussion
The IGFBPs are a complicated group of proteins with a variety of functions both 
dependent and independent of IGFs. In this study the effects of WCE from the American 
cranberry (Vaccinium macrocarpon) on expression of IGF-I and several IGFBPs in 
DU145 and PC3 cells in vitro has been examined. WCE was observed to induce 
significant changes in IGF-I and several IGFBPs after 24 h. The most interesting changes 
occurred in the expression of IGF-I, IGFBP-2 and IGFBP-5 which were significantly 
reduced in DU145 cells and PC3 cells.
 IGF-I is a growth factor which is normally expressed at peak levels during 
puberty, at which point expression gradually decreases with age (Furlanetto et al. 1994). 
The function of IGF-I is to increase cellular uptake of amino acids and promote 
carbohydrate metabolism through stimulation of glycogen and protein synthesis (Yu and 
Rohan 2000). IGF-I can also act as a potent mitogen by increasing DNA synthesis and 
stimulation of cyclin D1, causing the cell cycle to progress from G1 to S-phase, and 
suppression of cyclin D1 can abolish the mitogenic effect of IGF-I (Furlanetto et al. 
1994; Mawson et al. 2005). The decrease in IGF-I observed in the present study 
corresponds to a decrease in cyclin D1 expression in DU145 cells exposed to WCE in 
vitro reported by Déziel et al. (2012). IGF-I expression is associated with increased 
expression of cyclin D1 and CDK4 in MCF-7 cells (You et al. 2002), both of which are 
observed to decrease in DU145 cells in response to WCE by Déziel et al. (2012). Déziel 
et al. (2012) also observed that cell cycle arrest occurred in the G1 phase; cyclin D1 and 
CDK4 are two cell cycle proteins responsible for the induction of S-phase in the cell 
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cycle. This suggests that decreased IGF expression, as observed in the present study, may 
be in part responsible for arrest of the cell cycle in DU145 cells in response to cranberry. 
 Apoptosis is also inhibited by IGF-I through increased expression of Bcl proteins 
which acts to suppress Bax (Yu and Rohan 2000). The reduced expression of IGF-I 
observed in this study supports previous work done on the apoptotic effect of WCE. 
MacLean et al. (2011) found that DU145 cells exposed to 10 and 100 µg/ml WCE for 6 
and 24 h exhibited increased expression of Bax. As the ratio of Bax to Bcl is used to 
determine if apoptosis will occur, MacLean et al. (2011) concluded that the balance of 
these two protein may favor apoptosis after WCE treatment. The decrease in IGF-I 
expression observed in the present study may be one factor contributing to the previously 
observed increase in Bax expression.
 IGF-I has previously been found to increase MMP-2 and MMP-9 activity in 
DU145 human prostate cancer cells (Saikali et al. 2008). Similarly to the WCE associated 
cell cycle arrest and anti-apoptotic effects, previous studies have associated exposure to 
WCE (MacLean et al. 2007) and proanthocyanidins derived from whole cranberry 
(Déziel et al. 2010) to the inhibition of MMP-2 and MMP-9 activity. Extract fractions 
from the lowbush blueberry (Vaccinium angustifolium) containing anthocyanins and 
proanthocyanidins have also previously been found to inhibit MMP-2 and MMP-9 in 
DU145 cells in vitro (Matchett et al. 2005). Matrix metalloproteinases (MMPs) allow 
cancer cells to penetrate the vasculature and spread to other parts of the body by 
degrading the extracellular matrix (Nemeth et al. 2002). Déziel et al. (2010) observed a 
significant reduction in MMP-2 and MMP-9 activity in response to cranberry PACs 
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exposure at 25 µg/ml for 3 h. As the WCE used in the present study contained 41% PACs 
by weight, it is suggested that decreased IGF-I expression and decreased MMP activity 
may be associated with the PACs present in the WCE used in this study. Furthermore, 
MMP activity as well as expression of proteins modulating MMP activity such as tissue 
inhibitor of metalloproteinase (TIMP), reversion-inducing-cysteine-rich protein with 
Kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN) 
have also been shown to be affected by WCE in 0.1 mg/ml concentrations for a 6 h 
exposure (MacLean et al. 2007). The decrease in IGF-I observed in the present study 
could be one factor accounting for the changes in MMP expression in addition to WCE’s 
previously reported effects.
 IGFBP-2 has previously been observed to stimulate growth in cancerous prostate 
cells (DeGraff et al. 2007; Moore et al. 2003), and has been suggested as a potential 
biomarker of prostate cancer progression from androgen sensitivity to androgen 
independence (DeGraff et al. 2007, 2009). IGFBP-2 is known to be lysed by androgens 
(DeGraff et al. 2007, 2009; Moore et al. 2003) and castration in mice has been shown to 
increase IGFBP-2 expression (DeGraff et al. 2009). The proposed mechanism is that 
castration causes an increase in IGFBP-2 due to reduced proteolysis by androgens, which 
in turn serves to increase IGF activity (DeGraff et al. 2009).
 A reduction in IGFBP-2 has previously been associated with a decrease in IGF 
activity and a reduction in IGF-I half-life due to the loss of stability occurring when IGF-
I and IGFBP-2 are bound (Clemmons 1997). A loss of IGF-I due to increased proteolysis, 
caused by decreased IGFPB-2 expression meaning there is less available IGFBP-2 
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available to confer stability to IGF-I, can cause a decrease in IGF-I. This decrease in 
IGFBP-2 corresponds to the decrease in IGF-I found in the present study, and is likely 
involved in the cell cycle arrest, anti-apoptotic and anti-MMP activity observed in 
response to WCE and PACs in previous studies (Déziel et al. 2010, 2012; MacLean et al. 
2007, 2011; Neto et al. 2006).
 A reduction in the IGF-independent activities of IGFBP-2, such as the induction 
of proliferation and apoptotic resistance (DeGraff et al. 2009) is also observed in 
previous studies on whole cranberry extract through reduced growth and viability of 
DU145 cells (Déziel et al. 2012). It has also been suggested that IGFBP-2 functions 
differently in DU145 cells and PC3 cells, with IGFBP-2 acting primarily through 
modulation of IGF activity in PC3 cells but having both IGF-dependent and independent 
activity in DU145 cells, but the mechanism of this difference between cell lines has not 
been elucidated (Uzoh et al. 2011). This different mode of functionality could explain the 
discrepancy between results found in DU145 cells and PC3 cells, where a more 
pronounced IGFBP-2 expression decrease was observed in DU145 cells.
 No significant change was observed in IGFBP-3 expression in either DU145 cells 
or in PC3 cells after 24 h exposure to WCE at either concentration studied. IGFBP-3 is 
generally associated with the induction of anti-metastatic functions and acts as a tumor 
suppressor in mouse models (Mehta et al. 2011). Studies on grape seed 
proanthocyanidins in mouse models have shown increased expression of IGFBP-3 and 
associated suppression of IGF-I leading to anti-cancer effects (Akhtar et al. 2009). As 
such, it was unexpected that no change in IGFBP-3 would occur, but suggests that WCE 
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acts through expression of proteins other than IGFBP-3. It would be valuable to examine 
the effects of the various fractions of WCE, such as PACs, to determine if those fractions 
could induce a change in IGFBP-3.
 IGFBP-4 acts by inhibiting IGF-I action and therefore inhibiting cellular growth 
and proliferation (Clemmons 1997). As mentioned above, a decrease in IGF-I activity can 
lead to cell cycle arrest, anti-apoptotic and anti-MMP activity as observed in response to 
WCE and PACs in previous studies (Déziel et al. 2010, 2012; MacLean et al. 2007, 2011; 
Neto et al. 2006). Clemmons (1997) mentions that the main role of IGFBP-4 is in 
protecting cells from overstimulation by IGFs and that IGFBP-4 appears to be the only 
IGFBP to function solely in inhibiting IGF action. Previous studies have found that while 
over expression of IGFBP-4 does decrease growth of prostate cancer cells by inhibiting 
IGF action, a reduction in IGFBP-4 expression was associated with the induction of 
apoptosis as well (Durai et al. 2006). In vivo studies, in a mouse model, have shown that 
both an increase and a decrease in IGFBP-4 expression can delay tumor formation (Durai 
et al. 2006).
 An increase in IGFBP-4 has previously been associated with lowered expression 
of IGFBP-2 and increased expression of IGFBP-3 (Drivdahl et al. 2001). While a 
decrease in IGFBP-2 was observed in the present study, there was no significant change 
in IGFBP-3. IGFBP-4 expression was only significantly increased in PC3 cells at 50 µg/
ml WCE after 24 h, but not at the higher concentration.
 IGFBP-5 expression was significantly lower in both DU145 cells and PC3 cells at 
24 h in the presence of 100 µg/ml WCE in the present study. This decrease in IGFBP-5 
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expression may lead to a decrease in anti-apoptotic activity as described by Cobb et al. 
(2004) who observed that elevated levels of IGFBP-5 were associated with decreased 
apoptosis; this decrease in apoptosis occurred due to an inhibition of the intrinsic 
pathway of apoptosis and is independent of IGF. Inhibition of IGFBP-5 mRNA has been 
shown to inhibit cell proliferation, by causing cell cycle arrest, but did not affect 
apoptosis (Miyake et al. 2000). Likewise, decreases in IGFBP-5 expression have been 
associated with inhibition of IGF-I activities involving DNA synthesis and cellular 
metabolism (Clemmons 1997).
 This suggests that, like IGFBP-2, decreasing IGFBP-5 expression may inhibit 
progression from androgen sensitivity to androgen independence as up regulation of 
IGFBP-5 in prostate cancer cells after castration helps to promote the proliferative effects 
of IGF-I (Miyake et al. 2000). As with IGFBP-2, decreasing IGFBP-5 expression will 
result in a loss of bioavailability of IGF-I which in turn will result in a decrease in cyclin 
D1 expression and therefore inhibit progression through the cell cycle (Furlanetto et al. 
1994). This is supported by in vivo models where IGFBP-5 was found to have no effect 
on apoptosis but functioned in regulating the cell cycle in prostate cancer cells in a rat 
model (Thomas et al. 1998). The IGF-independent activity discussed by Cobb et al. 
(2004) would also suggest that the decrease in IGFBP-5 expression will lead to an 
increase in apoptosis observed by MacLean et al. (2011).
 WCE also decreases IGF-I expression through two approaches: directly 
influencing IGF-I expression and indirectly influencing IGF-I expression through 
alterations to IGFBP expression. This dual approach to decreasing IGF-I expression could 
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cause the inhibition of cyclin D1 expression and the induction of Bax expression as 
observed in previous studies (Déziel et al. 2012; MacLean et al. 2011) on WCE and 
further provides support that WCE can cause an arrest of cell cycle and the induction of 
apoptosis as previously described.
 Finally, further research studies examining the effect of enriched fractions of 
WCE (including PACs, anthocyanins, flavonols, ursolic acid and its esters, etc.) on IGF-I 
and the IGFBPs to determine what components of WCE are active in affecting IGF and 
IGFBPs in prostate cancer cells in vitro are warranted.  Future projects are currently 
planned to describe the signaling pathways controlling IGF and IGFBP expression.
 In conclusion, the IGFBPs are part of a complex group of proteins in the IGF 
family and are primarily responsible for the regulation of the IGFs. Exposure to WCE can 
affect IGF and IGFBP expression in DU145 and PC3 prostate cancer cells in vitro 
causing a decrease in IGF-I, IGFBP-2 and IGFBP-5 expression, and an increase in 
IGFBP-4 expression. These changes in expression of the IGFBPs may be responsible for 
inhibition of IGF activity, causing a reduction in the proliferative and anti-apoptotic 
effects of the IGFs. It has also been suggested that an increase in IGFBP-2 and IGFBP-5 
expression is correlated with the transition from androgen sensitivity to androgen 
independence in prostate cancer cells. In demonstrating that IGFBP-2 and IGFBP-5 
expression is decreased by exposure to WCE, it is possible that this may hold future 
potential as a method to block expression of these two proteins and thereby delay prostate 
cancer progression in this manner.
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